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Abstract: In most developed cOLmtries, prevention programs using Pap screening have 
resulted in impressive decreases in cervical cancer morbidity aud mortality over the past 
50 years. However, in the developing world, it is quite a different story. In these 
countries, where over 80% of cases occur, cervical cancer is the leading cause of cancer 
death among women (Pisani, Parkin and Ferlay 1999). Globally, cervical caucer has been 
estimated to account for 2.1% of deaths among women aged 25-64, but in Latin America 
it accounts for 3.8% of these deaths (Parkin, Bray aud Ferlay 2001). Because women in 
these age groups are fundamental to the fabric oflife, not just within families but within 
economies aud societies at large, the toll of this disease is significant. The reasons for this 
disproportionate burden throughout Latin America are not yet completely understood but 
are thought to be due in part to the high prevalence of human papilloma virus (HPV) and 
au inadequate health infrastructure to deal with incident cases (Eluf-Neto and Nascimento 
2001). I suggest that this burden is also due to the inadequacies of current prevention 
programs. 
This is au ideal time to reconsider cervical cancer prevention in the developing world. 
We now have a clear understanding of cervical cancer as a rare but possibly fatal 
complication of a sexually transmitted disease. After several decades of research, we 
know that HPV is a necessary but not sufficient cause of cervical cancer (W alboomers, 
Jacobs and Mauos 1999). New methods for detecting infection with HPV, as well as new 
techniques for detecting cervical dysplasia, provide a unique opportunity to re-examine 
our efforts to decrease suffering from this preventable illness, especially in the 
developing world. Aside from medical advances, international collaboratives such as the 
Alliance for Cervical Cancer Prevention ( ACCP) are directing fimding, research, and 
model programs toward preventing cervical cancer, particularly in the developing world. 
We need to evaluate the potential effects of this confluence of new technology, 
knowledge, and interest among international donors on this important women's health 
ISSUe. 
In this paper, I analyze the most effective way to approach cervical caucer prevention in 
Honduras. Honduras has a twenty year history of a national, Pap-based prevention 
program yet still suffers from mortality rates approximately five times higher than those 
in the United States. In an effort to re-consider these efforts, I examine three different 
cervical cancer prevention policies: the government's current Pap-based approach; a see-
and-treat approach (visual inspection with acetic acid followed by cryotherapy as 
necessary); aud HPV vaccines. Using the medical and health systems literature, field 
notes, aud key informant interviews, I evaluate each of these strategies along the 
following six criteria: efficacy, effectiveness, cost-effectiveness, acceptability, feasibility 
and equity. Despite significant resistance on the part of providers, I recommend a see-
and-treat approach as the most cost-effective aud equitable policy for decreasing cervical 
cancer incidence and mortality in Honduras. 
Introduction 
As with antibiotics and childhood immunizations, the Papanicolau (Pap) smear is 
considered to be one of the major public health successes of the last century. 
Used as a tool to screen for cervical cancer, the Pap smear has been an integral 
part of effective cervical cancer prevention programs. In most developed 
countries, prevention programs using Pap screening have resulted in impressive 
decreases in cervical cancer morbidity and mortality over the past 50 years. 
However, in the developing world, it is quite a different story. 
Cervical cancer causes a disproportionately high degree of morbidity and 
mortality in the developing world. World-wide, cervical cancer is the second most 
frequent cancer and the fifth most frequent cause of death from cancer among 
women (Yang, Bray and Parkin 2004). In the developing world, where over 80% 
of cases occur, cervical cancer is the leading cause of cancer death among women 
(Pisani, Parkin and Ferlay 1999). Globally, cervical cancer has been estimated to 
account for 2.1% of deaths among women aged 25-64, but in Latin America it 
accounts for 3.8% ofthese deaths (Parkin, Bray and Ferlay 2001). Because 
women in these age groups are fundamental to the fabric of life, not just within 
families but within economies and societies at large, the toll ofthis disease is 
significant. The reasons for this disproportionate burden throughout Latin 
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America are not yet completely understood but are thought to be due in part to the 
high prevalence ofhmnan papilloma virus (HPV) and an inadequate health 
infrastructure to deal with incident cases (Eluf-Neto and Nascimento 2001). I 
suggest that this burden is also due to the inadequacies of current prevention 
programs. 
For the past three years I have worked with a team of medical students and faculty 
to develop a reproductive health education and prevention program for rural 
Honduran women. The impetus for this annual month-long service project is 
Honduran women's expressed fears of cervical cancer as well as the widely held 
misunderstanding that contraception is causing cervical cancer. These women's 
fears, although not fully informed, are legitimate. In Honduras, cervical cancer 
mortality rates are almost quadruple what they are here in the United States. Thus, 
despite over a decade of Pap-based prevention programs, the impact of cervical 
cancer in Honduras is still large, and it disproportionately affects poorer and less 
educated women (Ferrera, Velema and Figueroa 2000). 
The toll exacted by cervical cancer makes this is an ideal time to reconsider 
cervical cancer prevention in the developing world. We now have a clear 
understanding of cervical cancer as a rare but possibly fatal complication of a 
sexually transmitted disease. After several decades of research, we know that 
HPV is a necessary but not sufficient cause of cervical cancer (Walboomers, 
Jacobs and Manos 1999). New methods for detecting infection with HPV, as well 
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as new techniques for detecting cervical dysplasia, provide a unique opportLmity 
to re-examine our efforts to decrease suffering from this preventable illness, 
especially in the developing world. Aside from medical advances, international 
collaboratives such as the Alliance for Cervical Cancer Prevention (ACCP) are 
directing funding, research, and model programs toward preventing cervical 
cancer, particularly in the developing world. We need to evaluate the potential 
effects of this confluence of new technology, knowledge, and interest among 
international donors on this important women's health issue. 
In Honduras, which is the locale of our intervention as well as the focus of this 
paper, specific changes in the health care sector also make this an ideal time for 
reconsidering cervical cancer prevention efforts. Despite severe economic 
constraints, the current administration has voiced a commitment to health sector 
reform (The Economist Intelligence Unit 2004) and international donor agencies 
are responding. In February ofthis year, the World Bank approved a $25 million 
credit to assist development of the financial sector and to promote long-term 
economic growth and poverty reduction (World Bank 2005). This level of 
commitment implies faith in the current and future economic and political 
stability of the country. As Honduras moves through the demographic transition 
already experienced in many Latin American countries, development efforts 
including family planning programs will continue to spread to rural areas and 
women will continue to have questions and concerns about their reproductive 
health. 
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Currently, the Honduran Ministry of Health recommends screening Pap smears 
for sexually active women aged 30 to 59. Adherence rates to this policy are 
relatively high, with approximately 60% of women reporting having had a Pap 
smear in the past year (Secretaria de Salud 2002). However, after this screening 
test, many women, especially in rural areas, never get their results. Even when 
they do, their lack of knowledge often limits a clear understanding of the meaning 
of test results. Moreover, the financial and time investments required for follow-
up care put it beyond the means of many women (Morse and Saleeby 2003). 
Thus, current cervical cancer screening and prevention programs in Honduras are 
not associated with significant decreases in morbidity and mortality rates. 
The World Health Organization advocates two major components of successful 
early cancer detection: education and screening (WHO 2004). The educational 
components of a prevention program can be instrumental not only by encouraging 
screening, but also by contributing to behavior change processes that lead to 
decreased risk. In much of Latin America, this educational process is often 
spearheaded by lay health advisors (LHAs), community members with additional 
training who serve as health resources in traditionally underserved areas. 
Although much research is being done on this fundamental part of a 
comprehensive prevention program, analysis of the effectiveness ofthese LHA 
health education programs is outside of the scope of this work1 This paper will 
1 For additional information on the educationaVcommunity development part of this intervention 
as it relates to LHAs, please see Erin Saleeby's master's paper. 
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instead focus more specifically on which screening modalities are most effective 
for cervical cancer prevention programs in Honduras. Some of these modalities, 
specifically visual inspection with acetic acid (VIA) and vaccines, can make use 
ofLHA's basic health training and status in the community to facilitate 
widespread implementation of prevention programs. 
Within this context, the aim of this paper is to make recommendations about 
effective cervical cancer screening policies in Honduras. I will analyze one 
primary prevention approach and two secondary prevention approaches: (1) the 
government's current policy regarding the use of Pap smears; (2) the use of VIA, 
also known as a "see and treat" method; and (3) primary prevention via an HPV 
vaccme. I will use the following criteria- efficacy, effectiveness, cost- L 
effectiveness, equity, acceptability and feasibility- to evaluate each of these 
policies. Based on this analysis, I make recommendations for implementation of 
cervical cancer prevention policies appropriate to Honduras. The following pages 
offer evidence and support for the need to re-consider the current Pap-based 
prevention program in Honduras and recommend a shift to VIA with immediate 
treatment by cryotherapy as a more effective and equitable strategy to reduce the 
impact of cervical cancer. 
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Background 
Natural History of Cervical Cancer 
Cervical cancer is a progressive neoplastic syndrome of the cells of the cervix. 
Although most invasive cancer arises from squamous cells, about 20% of cervical 
cancer, known as adenocarinoma, is associated with dysplastic glandular cells 
(Waggoner 2003). Over a period of years, cervical cells, either squamous or 
glandular, can develop changes resulting in precancerous or cancerous forms. The 
progression can range from cervical intraepithelial neoplasia (CIN) to squamous 
intraepitheliallesions (SIL) to carcinoma in situ and eventually to invasive cancer. 
Dysplastic changes may begin early in life, but the pre-invasive period is quite 
long, lasting decades. Hence, most women who are affected do not develop 
cancer until their late forties or fifties. During this pre-invasive period, the risk of 
metastasis is low, and appropriate treatment can be curative, making cervical 
cancer well suited for screening. 
Treatment is based on the depth and extent of spread of lesions. For pre-invasive 
lesions, treatment can be performed on an outpatient basis using ablative or 
excisional procedures. Cryotherapy, the most common ablative procedure, 
involves spraying compressed carbon dioxide (C02) or nitrous oxide (N02) on to 
the diseased part of the cervix to kill the pre-cancerous cells. The procedure poses 
very few risks and requires only minimal medical follow-up. In general, it is 
minimally invasive, low-tech and very effective, even relative to more invasive 
treatments. Unlike excisional procedures, cryotherapy does not provide a sample 
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for histologic confirmation of the diagnosis. Loop electrosurgical excision 
procedure (LEEP), the most common excisional treatment, involves the physical 
removal of abnormal cells with an electrosurgical wire loop. It is also very low-
risk but requires a more skilled provider and is usually done with colposcopic 
guidance. Both of these treatments have proven to be very effective in the 
treatment of CIN (Martin-Hirsch, Paraskevaidis and Kitchener 2004; Zasislak, 
Price, and McClelland 2003). For invasive cancers, major procedures such as 
radical hysterectomy, sometimes accompanied by chemotherapy or radiation 
therapy, are necessary. Without treatment, the cancer can metastasize to distant 
sites and result in death. 
Morbidity from cervical cancer can include minor symptoms such as postcoital 
bleeding and pelvic pain. However, for non-metastatic cases, most of the 
morbidity stems directly from the treatment. Although most women with invasive 
cancer are past their childbearing years, infertility from surgery, radiation 
treatment, or chemotherapy is one of the major morbidities. Additionally, 
chemotherapy can result in significant nausea and vomiting, as well as hair loss 
and immunosuppression. Radiation treatment, although localized, can lead to 
burning and scarring of nearby tissues. Many women also experience significant 
psychological morbidity, whether from the cancer itself, or from fear of pain, 
infertility, or death. 
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Over the last decade, the pathophysiology of cervical cancer, and the link to HPV, 
has become better understood. Human papilloma virus, thought to be the most 
widespread as well as the oldest sexually transmitted infection in humans (Tjalma, 
Arbyn and Paavonen 2004; Lehitnen and Paavonen 2003), is now known to be 
central to the development of cervical neoplasia (Walboomers, Jacobs and Manos 
1999). HPV infection alone is not enough for development of cervical cancer; it is 
thought to be a necessary but not sufficient cause. Many HPV infections, 
especially in young women, are transitory and regress spontaneously without ever 
resulting in any cervical cell changes. When infections are persistent, they can 
lead to dysplastic changes. Over 99% of cervical cancers and their precursor 
lesions (CIN) contain HPV DNA (Schreckenverger and Kaufmann 2004). 
Although over I 00 strains ofHPV are thought to exist, only some appear to be 
oncogenic. Eighty percent of cervical cancers are associated with four high risk 
HPV types, types 16, 18,31 and 35. Type 16 alone is thought to be present in 
approximately 50% of cancers (Schreckenverger and Kaufmann 2004). 
In Honduras, the association between HPV infection and the subsequent 
development of cervical cancer is not tmiversally recognized by providers 
throughout the country (Morse and Saleeby 2003). This is despite the well 
documented high prevalence ofHPV and cervical cancer there. In a recent case-
control study published by Ferrera, Velema and Figueroa (1999), HPV was found 
to be highly prevalent (39%) even in their control sample. Data from Honduras 
are consistent with findings around the world. Human papilloma virus type 16 is 
8 
most commonly associated with invasive cancer cases, although the rate (42%) is 
somewhat lower than in other Latin American countries. Although Honduran 
rates of cancer associated with HPV 18 (1 0%) are comparable to that of other 
Latin American countries, rates ofHPV 58 (6.5%) associated with invasive 
cervical cancer are almost double that typically found in other parts of Central and 
South America. These minor differences could be significant ifHPV vaccines 
become a central component of cervical cancer prevention policies (see pp 34 ff). 
Differences in HPV infection rates vary somewhat across the globe, although not 
as much as do differences in morbidity and mortality. World-wide, cervical 
cancer is the second most frequent cancer as well as the second highest cause of 
cancer-related morbidity and mortality among women (Yangh, Bray and Parkin 
2004; Parkin, Pisani and Ferlay 1999). This burden disproportionately affects the 
developing world, where more than 80% of cases occur. ln the year 2000, the 
World Health Organization (WHO) estimated that there were 471,000 new cases 
of cervical cancer diagnosed and 233,000 deaths worldwide (Parkin, Bray and 
Ferlay 2001). Approximately 92,136 of those cases and 37,640 of those deaths 
were in Latin America and the Caribbean (Lewis 2000). As I noted at the outset, 
cervical cancer is responsible for a higher proportion of deaths in 25-64 year old 
women in this region than anywhere else in the world. 
Honduras appears to share a large part of this burden. Based on national cancer 
registry data, cervical cancer is the most common malignancy and accounts for 
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40% of the cancer cases that need follow-up care and 50% of the cancers in 
women (Ministerio de Salud 2004). In the year 2000, the Pan-American Health 
Organization (P AHO) reported an age adjusted incidence and mortality rate in 
Honduras of39.6 cases per 100,000 women and 16.8 deaths per 100,000 women 
respectively (P AHO 2000). In an update on their cervical cancer prevention 
program in 2003, the Honduran Ministry of Health reported an incidence rate of 
40 cases per 100,000 women and a mortality rate of 40 deaths per 100,000 women 
(Ministerio de Salud 2003). Although this discrepancy in mortality figures likely 
reflects data collection differences, both are strikingly large compared to data 
from the United States, which in 2000 experienced an age-adjusted incidence rate 
of only 9.3 cases per 100,000 women and a mortality rate of2.9 deaths per 
100,000 women (J emal, Murray and Ward 2005). Unlike in the US, cervical i 
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cancer is the most common neoplasia among women in Honduras (Ferrera, 
Velema and Figueroa 1999) and in 1989-90 accounted for 4.9% of all deaths 
among women of childbearing age (PAHO 2001). 
Moreover, unlike much of the developed world, where cervical cancer mortality 
has decreased over the last thirty years, mortality has remained almost constant in 
Latin America. This has resulted in a greater burden of years oflife lost (YLL) in 
the developing world. Cervical cancer contributes over 2. 7 million YLL among 
women aged 25-64 around the world. However, 2.4 million of these YLL lost 
occur in the developing world and only 0.3 million occur in developed countries. 
Latin America and the Caribbean is the only world region where cervical cancer 
10 
is the leading component ofYLL (Eluf-Neto and Nascimento 2001). The WHO 
quantifies the burden of suffering in Latin America, reporting that cervical cancer 
now accounts for a loss of 471,000 daily adjusted life years (Lewis 2000). Exactly 
how much of this burden falls on Honduras has not been explicitly reported. 
Risk Factors 
Risk factors for cervical cancer are numerous and well-documented. Although 
women are usually over 35 when they are diagnosed, the disease is thought to 
begin much earlier, so risk factors early in life can influence development of 
cancer (Ferrera, Velema and Figueroa 1999). Universally agreed upon risk factors 
include HPV infection, having multiple sexual partners (or a partner who has 
multiple partners), early age at first intercourse, a history of sexually transmitted 
diseases, immunosuppression, low socioeconomic status, low educational status, 
and smoking. Recent research in Honduras suggests that exposure to smoke from 
wood burning stoves in the kitchen is also a risk factor for invasive cervical 
cancer, independent of other factors such as education, parity and number of 
sexual partners (Velema, Ferrera and Figueroa 2002). In the 2001 National 
Epidemiology and Family Health Survey, 55.9% of homes (25.4% of urban 
homes and 84.7% of rural homes) reported burning wood for cooking (Secretaria 
de Salud 2002). 
In a recent study examining risk factors for cervical cancer mortality in Mexico, 
Palacio-Mejia, Rangel-Gomez and Hem:'mdez-Avila (2003) found that poverty-
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related factors such as lack of formal education, unemployment, low-socio-
economic level, mral residence and insufficient access to health care were all 
significantly associated with higher risk of mortality from cervical cancer. They 
suggest that not just poverty, but also gender inequality, has an impact on the high 
mortality rates of cervical cancer in Mexico. Although Blanc's (2001) review 
focuses on reproductive health more broadly, she corroborates the idea that 
gender inequality, especially power differences within sexual relationships, can 
have a negative effect on women's reproductive health outcomes. Women's 
inequality within these relationships can affect their ability to protect themselves 
from risks, obtain information about reproductive health, or seek care as needed. 
Other investigators have proposed methods to mitigate some of these independent 
risks in a meta-analysis of studies in the developing world including a case-
control study in Honduras. These studies demonstrate that education is especially 
important in empowering women to foster lifestyles that result in decreased risk 
for cervical cancer. Involving men in prevention programs has also been shown 
to be important in developing programs that will be well accepted and accessible 
(Blanc 2001). Many of these gender-specific factors that put women at greater 
risk for disease overlap with the factors that make them less likely to get screened. 
Thus, without educating and empowering women, less wealthy and less educated 
women will continue to be disproportionately affected in terms of both incidence 
and mortality (Ferrera, Velema and Figueroa 2000; Parikh, Brennan and Boffeta 
2003). 
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The Honduran Context 
A basic understanding ofthe socio-demographic, economic, political and health 
care system dynamics that shape life in Honduras is essential to making sound 
policy recommendations. To that end, I will briefly describe the demographic 
factors relevant to cervical cancer prevention. I will also describe the Honduran 
health care system, as well as recent reform efforts that may open the door for 
policy change regarding cervical cancer prevention. 
The predominant social force of day-to-day life in Honduras is poverty. Despite a 
fairly stable political history relative to many of its Latin American neighbors, 
Honduras remains a poor country. In 200 I, per capita income in Honduras was 
$870.35, significantly lower than the average of$6,728 in the rest of Latin 
America (PAHO 2001). In relative tenns, this means that 66% of households fall 
below the poverty line, and 49% of these fall below the indigent line. Perhaps 
even more striking, especially in light of recent national efforts to combat poverty, 
is the increasingly tmeven distribution of resources. In 2001, the poorest 20% of 
the population received 4.3% of the income while the richest 20% received 59.3% 
(P AHO 2001 ). In 2004, Honduras ranked 115'h out of 177 countries on the 
Human Development Index2, with an overall score of0.672 and a gender-related 
) 
- The UN Human Development Index was developed in 1990 and is reported annually by the UN 
since 1993. The Index measures, among other things, povetiy, literacy, life expectancy and GDP 
per capita. It is considered to be a good indicator of both social and economic development. The 
gender -related development index uses the same variables but adjusts for gender inequalities in 
several key aspects of human development: life expectancy, literacy, gross school enrollment, and 
mcorne. 
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development index of only 0.662 (United Nations 2004). This low score reflects, 
in part, the adult literacy rate of 16.8% overall: 8.9% in urban areas and 23.3% in 
rural areas. Average schooling for adults is 4.3 years, with women generally being 
less educated than men (Bur lone 2003). Living conditions reflect these poverty 
levels, with 38% of rural women living in homes with open air latrines and 85% 
of them using wood fires in the horne for cooking (Secretaria de Salud 2002). 
These and other factors associated with poverty make the delivery of 
comprehensive preventive health services difficult. The rurality of Honduras is a 
particularly important variable. Fifty-six percent of the population lives in rural 
areas. Poverty tends to be concentrated in these areas, although marginalized 
zones in the two major urban areas are also growing. Despite a decrease in total 
fertility and crude birth rate over the past decade, the population is still growing 
and 53% of the population is under the age of 19, posing a major demand on the 
health care system in the years to come as they age and require more services. 
Although data to support the contention are virtually non-existent, migration 
appears to have an increasing effect on health care delivery, as well as on cervical 
cancer incidence. Many young men migrate locally to work on large farms or to 
urban areas in search of industrial work. Increasingly they are migrating to the 
United States as well. Away from their homes, they often adopt less restrictive 
sexual practices, resulting in increased spread of communicable diseases among 
their urban partners, as well as an introduction of those diseases to their rural 
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partners (Linthicwn 2004). My experience in Southern Honduras reveals that 
most migrating men leave families in rural areas but return home to them. Thus, 
human movement and changes in sexual behaviors may increasingly affect the 
spread of HIV, HPV, and the incidence of cervical cancer. 
These challenges confront a health sector that is predominantly driven by the 
Ministry of Health (MoH). The MoH assumes all regulatory responsibility and is 
also the main, public provider of care. Operating hospital and ambulatory care 
networks that are linked together by a very weak referral system, the MoH 
provides care to just over half of the population (P AHO 2001; Omaha, Melendez 
and Uehara 1998). The Instituto Hondurefio de Seguridad Social (Honduran 
Social Security Institute, or IHSS) serves much the same role as does Medicare 
and covers about 10% of the population. Although the private health sector is 
growing, it covers only about 10-15% of the population, mainly through for-profit 
clinics and hospitals and a small insurance market. Some non-governmental 
organizations (NGO) or church-sponsored non-profit providers exist, but they 
represent only a small fraction of health care services. Unlike the public sector, 
the private sector devotes few resources to public health activities. 
This analysis will focus primarily on the MoH, not only because it is the main 
public provider of care, but also because it is engaged in the function of health 
promotion, health protection, and health recovery. Moreover, along with the 
Ministry ofthe Presidency, the MoH, through its Management, Planning and 
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Evaluation Unit, is tasked with planning and developing national health policy. 
Although the main source of financing for this system is taxes, as recently as 
1999, foreign fimds contributed 37% of the monies spent in the public health 
sector (The Economist Intelligence Unit 2004). Data on health care expenditures 
per capita vary widely depending on the source. Figures range from $49 per capita 
in 2001 to $165 per capita in 2004, putting it below all of its neighbors except 
Nicaragua (The Economist Intelligence Unit 2004). Regardless of the exact 
figure, resources are limited to fund the changes that need to be made to create a 
more effective, accessible system. 
Changes to the health care system, as well as general social and economic 
development, remain on the political agenda, at least in rhetoric. Health sector 
reform was espoused in 1990, but no official policies were developed or 
implemented during state modernization efforts at that time. In 1999, as part of 
post-Hurricane Mitch reconstruction efforts, the government established "1999-
2001 Policy Guidelines" to meet population concerns about equity, quality, 
solidarity and citizen participation in the use and delivery of health care. Since 
that time, the MoH has created the Technical Council on Management and 
Institutional Development. Although it is responsible for developing an 
improvement plan, no goals have been outlined, nor new programs implemented. 
Thus, the health sector continues to have major problems in the areas of health 
care access, information systems (for disease surveillance and reporting and 
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general health statistics), human and technical resources, and quality and licensing 
standards. 
Each of these problem areas is significant to a consideration of implementing a 
cervical cancer prevention program. Access to care, especially screening services, 
is of great concern, especially for poor, rural women or women living in 
marginalized urban areas. In the communities where I have worked, most of the 
women must travel by foot, or first by foot and then by bus, to reach a health 
outpost, which is typically staffed by a nurse or a community health worker. To 
get a Pap smear, most women in these communities go to the closest outpost or 
wait until a Cuban doctor, who does outreach to rural communities, is in town. 
Once at the health post, if more advanced care is needed, they take a bus for over 
an hour to reach a city with fully-staffed clinics and a hospital. The links between 
these different levels in the health care system are weak, at best, resulting in less 
than ideal referral processes. These experiences seem fairly typical for the 
majority of the population that lives in rural areas. 
The lack of good data collection efforts exacerbates the challenges posed by 
physical distances, and makes the referral process much more cumbersome. 
Electronic data collection is not feasible because of cost constraints and the 
undependable electricity supply in many ofthe rural outposts. Thus, 
recordkeeping, at least in the non-urban centros (health care centers/rural 
outposts) is completely paper-based. A recent report by P AHO suggests 
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significant underreporting of deaths (47%), as well as problems in indicating the 
exact cause of death (P AHO 2001 ). Despite the initiation of a national cancer 
registry at the main hospital in the capital city of Tegucigalpa, we probably do not 
know the full impact of cervical cancer morbidity and mortality. 
The two other main weaknesses affecting cervical cancer prevention programs are 
a general lack of health care infrastructure, both human and physical, and a lack 
oflicensing guidelines and quality standards throughout the health care system. 
Despite recent increases in the physician and nursing workforce, the human 
capital in the public sector is still quite limited. In 1999, Honduras had 8.7 
physicians per 10,000 people, 3.2 nurses, and 0.6 mid-level laboratory 
technicians. Consideration of these workforce limitations is fundamental to 
establishing a more effective cervical cancer prevention policy. Associated with 
these workforce limitations are physical limitations, such as 2.03 clinical 
laboratories per 100,000 inhabitants. For a screening program based on cytology 
or HPV DNA testing, this lack of adequate lab resources is a significant barrier to 
prompt processing of tests. Delays in return of results raise serious concerns about 
loss to follow-up. Although I have not been able to locate data specific to 
Honduras about loss to follow-up, Gage, Ferreccio and Gonzales (2003) suggest 
that in developing countries, the percentage can be as high as 80%. My 
experiences in Honduras do not contradict this. In addition to these human and 
physical infrastructure shortages, a lack of standardized guidelines for health care 
provider licensing and accreditation, as well as maintenance and quality control of 
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labs and other facilities poses major challenges to effective screening and 
prevention. 
Despite what may seem to be a fragile system, there are numerous successes as 
well as initiatives for reform that make this an ideal time to be re-assessing 
cervical cancer prevention efforts. One of the most recent successes has been a 
significant decrease in maternal mortality. From 1990-1997, Honduras' maternal 
mortality rate fell 40%, from 182 per 100,000 live births to 108 per 100,000 live 
births (Shiffman, Stanton and Salazar 2004). This precipitous reduction, the 
largest ever documented in such a short period of time in the developing world, is 
. 
thought to be due, in part, to the cooperative relationships that developed between r 
international donors and national health officials. This bodes well for openness to 
improving other parts of women's health, including cervical cancer prevention, 
especially considering the significant interest of several international agencies 
(Pan American Health Organization (P AHO), the Alliance for Cervical Cancer 
Prevention (ACCP)) as well as donors (Bill & Melinda Gates Foundation, the 
World Bank) in addressing this global problem through new technologies adapted 
to the developing world. 
A second recent victory is the decrease in measles, with no reported cases for the 
years 1997-1999. This accomplishment illustrates the ability of the MoH to 
implement and sustain a comprehensive and effective national immunization 
program. This success also suggests that, ifHPV vaccines are a reasonable option 
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for cervical cancer prevention in Honduras, there are replicable model programs. 
The third promising trend is a recent examination by the MoH ofPAHO's 11 
essential public health functions, which coincided with an increase in spending on 
health promotion and preventive care. Thus, the success of effective models as 
well as internal and external policy agendas make this an ideal time to re-examine 
and improve Honduras' cervical cancer prevention strategies. 
The Key Players 
Although the MoH and other Honduran institutions are clearly the key institutions 
in determining any changes to Honduras' national prevention efforts, two 
international agencies merit mention because oftheir significant influence in 
international cervical cancer prevention efforts, especially in the developing 
world. 
The Alliance for Cervical Cancer Prevention 
Started in 1999 with funding from the Bill & Melinda Gates Foundation, ACCP is 
a consortium of five international agencies that are working together to invigorate 
a global campaign to prevent cervical cancer. The Alliance coordinates research 
and program implementation efforts to help develop effective strategies for 
prevention in the developing world. The Alliance is made up of a collaboration of 
the following five agencies: Engender Health, IARC (International Agency for 
Research on Cancer), JHPIEGO (an affiliate of Johns Hopkins University), 
PAHO, and PATH (Program for Appropriate Technology in Health). 
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The Pan-American Health Organization 
P AHO serves as the regional office of the World Health Organization (WHO) for 
all of the Americas and falls under the rubric of the United Nations. As a public 
health agency with over 100 years of efforts to improve the public health and 
living standards throughout the Americas, P AHO serves a vital role in granting 
monetary and technical assistance, setting health policy standards and guidelines, 
and collecting data and conducting research to meet the specific public health 
needs of the countries in the Americas. These services often provide crucial 
resources for countries with limited means. At least in the United States, P AHO's 
affiliation with the UN and its status as an international, non-partisan agency, 
lends credibility and legitimacy to their data and program and policy guidelines, 
which are thought of as non-biased or neutral. i-
The Current Policy 
The current cervical cancer prevention program in Honduras was developed in 
1991 as part of the National Program for Cancer Control. The program is 
specifically targeted at women aged 30 to 59, but the MoH recommends that all 
women get Pap smears every three years after the onset of sexual activity. The 
program is focused around decentralized sample collection with centralized 
processing at one of three regional labs. In May, 2002, the MoH carried out a 
major re-examination of the state of cervical cancer in Honduras, as well as an 
evaluation of the program's major successes and failures as part of a two-year 
"Strengthening Project". The report generated from this investigation, which 
received 65% of its funding from international donors, found three major 
21 
problems contributing to the high incidence of cervical cancer: (1) a low demand 
for cytology services; (2) a poorly linked network of health services; and (3) a 
lack of compliance with the "Manual of Norms and Procedures for the Prevention 
and Control of Cervical Cancer"3 This combination of shortcomings was reported 
to be responsible for the high morbidity and mortality from cervical cancer, as 
well as the major economic and social investments required to care for patients 
who present in the advanced stages of cancer. 
The MoH used these findings to set out three specific objectives for the 
"Strengthening Program" to improve cervical cancer prevention: (1) increase Pap 
screening rates and coverage areas; (2) improve the linkages between health 
services; and (3) apply the recommendations laid out in the "Manual." Ancillary 
activities to help meet these objectives include a bilateral educational campaign 
targeted at women and health care providers. The general education for women is 
focused on risk factors and the importance of Pap smears. For health care 
providers, the focus is the guidelines detailed by the Manual, with an emphasis on 
the quality of samples, interpretation of results, and the provision of appropriate 
referrals. Provider training spans across care levels, from nurses to gynecologists, 
and across the health sector, including providers from both public and private 
facilities. 
3 Unfortunately I have not been able to obtain a copy of this "Manual". However, based on other 
manuals I have seen regarding h·eatrnent of sexually transmitted diseases, my best assumption is 
that the manual offers explicit documentation about the norms for screening and treatment of 
cervical cancer. 
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At a PAHO meeting in February, 2003, representatives from the MoH reported 
that the "Strengthening Project" has made several improvements toward meeting 
these goals. In the area of increasing Pap screening rates and coverage, several 
day training sessions were held for providers to increase their prevention 
knowledge and skills. In the area of improving linkages between the network of 
health care services available, significant improvements were reported but not 
detailed. Of note, the average time for return of Pap results dropped from three 
months to 30 days after the "Strengthening Project's" introduction. Although 
there are still exceptions, this change is significant. 
Screening Methods 
Pap Smears 
Pap smears, named for their inventor, Dr. George Papanicolau, offer a method for 
detection of abnormal cervical cells. The theory behind a Pap smear, also known 
as cervical cytology, is that changes in nuclear protein color and size that are 
associated with HPV infection and cancer development can be detected via 
microscopic examination of a sample of cervical cells. The actual process 
involves using a speculum to gain access to the cervix, and then collecting a 
sample of ectocervical cells with a paddle and endocervical cells with a thin brush 
that is inserted into the cervical canal. The cells are immediately smeared on a 
glass slide, fixed, and sent to a laboratory for examination by a cytotechnician and 
final reporting by a cytopathologist. Although uncomfortable, in the absence of 
any infection or other pathology, the procedure is usually not painful. 
Results from a Pap smear, which can take anywhere from days to weeks, 
depending on the laboratory, serve only as a screening tool. They are not 
diagnostic but instead offer guidance about further examination. Results are 
reported by the level of cellular change noted. In 2001, a new reporting system, 
based on the degree of cellular change, or atypia, was adopted to allow for 
standardization between labs and clinicians. The new categorizations, designated 
the Bethesda System, characterize results as ASCUS (atypical squamous cells of 
undetermined significance), LSIL (low-grade squamous intraepitheliallesion) or 
HSIL (high-grade squamous intraepitheliallesion). Depending on the results, 
follow-up testing may include nothing other than continuing to get Paps at the 
recommended interval, repeating the Pap, colposcopy, or colposcopy with a 
biopsy. A colposcope allows a clinician to get a magnified view of cervical tissue 
and facilitates collecting a sample for biopsy. 
Despite their widespread use, there has never been a randomized trial of the 
efficacy of cytologic screening for cervical cancer (Shingleton, Patrick and 
Johnston 2005). At this point, Paps are so widely used that such a trial will never 
be done. Observational trials in five Nordic countries comparing cervical cancer 
mortality before and after implementation of screening programs demonstrated 
reductions of8-73% (Laara, Day and Hakama 1987). In the United Kingdom, 
recent debate over health care expenditures has called into question the value of a 
Pap-based prevention program. In response, Peto, Gilham and Fletcher (2004) 
analyzed and projected cervical cancer mortality rates before and after the 1988 
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launch of a national screening program. They suggest that 80% of projected 
cervical cancer deaths have been prevented in the United Kingdom due to the 
screening program. Although there are significant limitations to their 
methodology, an effect even half as large as was found is fairly impressive. In 
spite ofthis evidence, which has been supported in numerous developed countries 
with comprehensive screening programs, it is still prudent to question the efficacy 
of cytology as a screening tool, especially in the developing world. 
The accuracy of a Pap's detection of precancerous lesions is not established, and 
reported results vary. Published papers report divergent numbers for both 
sensitivity and specificity. The most recent review, published by Nanda, McCrory 
and Myers in 2000, compared 94 studies that used Pap testing with a reference 
standard (histology, colposcopy or cytology). In the 12 least biased studies 
reviewed, sensitivity ranged from 30-87% and specificity ranged from 86-100%. 
These figures are fairly consistent with the munbers reported by Fahey, Irwig and 
Macaskill in a review conducted in 1995. As, Nanda, McCrory and Myers point 
out, two major weakness in many Pap accuracy studies include selection bias and 
verification bias. Often, accuracy is assessed in a high prevalence group, such as 
women presenting to clinic for colposcopy after an abnormal Pap. Moreover, 
many studies verify only positive results with the gold standard. Both of these 
biases can make Paps appear more accurate than they are. The authors caution 
policy makers to use the low end of reported accuracy ranges, especially when 
conducting cost-effectiveness analyses. 
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The need for caution in applying these results to health policy decisions is 
especially true in the developing world. Although the two reviews described 
above are currently our best information, they rely on studies done in developed 
countries where greater access to resources often results in better accuracy due to 
better training of providers, better maintenance of laboratory equipment, and 
improved data collection. A recent assessment of cytology accuracy in developing 
countries based on six cross-sectional studies fouud that sensitivity ranged from 
44% to 78% and specificity ranged from 91% to 96% (Sankaranaryanan, Gaffikin 
and Jacob 2005). 
The wide range of sensitivity and specificity reported in the literature is not just 
due to differences in study design or geographic location. These figures range so 
widely in part because a Pap's accuracy varies with respect to the degree of 
dysplasia to be detected. Paps are generally more accurate at detecting more 
serious, high grade dysplasia. Thus, if a trial uses detection of low-grade 
dysplasia, the sensitivity appears lower than if measured for detecting invasive 
cancer. As the threshold for the test increases, sensitivity increases but specificity 
decreases (Nanda, McCrory and Myers 2000). Unfortunately, Pap sensitivity 
ranges quite widely, resulting in false negative rates of 6 to 55% in some trials 
(Shingleton, Patrick and Johnston 1995). Thus, the false negative rate, even in 
women with invasive cancer, can be concerningly high. Two-thirds of these false 
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negative results are thought to come from sampling errors, whereas the remainder 
is from detection error (Nanda, McCrory and Myers 2000.) 
Accuracy is greatly affected by the adequacy of the sample, how it is fixed and 
stained, and the abilities of the cytotechnologist (Shingleton, Patrick and Johnston 
1995). An inadequate or contaminated (bloody) sample is often unreadable. 
Inadequate smears, often a product of poorly trained providers, can have a 
significant impact on a program's success. In a recent study in Peru looking at 
ways to improve Pap accuracy, 13.8% of smears were found to be inadequate for 
reading. In post-menopausal women whose endocervix is involuted, accuracy is 
often lower even with the use of endocervical brushes to collect the sample. 
Efforts to improve Pap's accuracy include liquid-based cytology and computer-
assisted cytology, both of which are still being assessed in the developed world 
and lie outside the financial reach of most developing countries. Despite 
variations in accuracy, there appears to be general agreement that high-quality 
Pap smears are very specific but their sensitivity is variable, at best. 
In many respects, Pap-based prevention programs are resource-intensive. They 
require three types of health care personnel: a doctor or nurse to collect, prepare 
and fix the smear; a cytotechnician to process, stain and read the smear; and a 
cytopathologist who can supervise and accept ultimate responsibility for final 
reporting of results. Training for cytotechnicians is fairly extensive, often lasting 
for 12 to 24 months. Aside from human resources, cytology necessitates a 
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laboratory infrastructure, quality-control mechanisms, and information processing 
to get results back to women. Pap-based programs also require at least two, but 
usually three visits by the patient: a screening visit, a follow-up visit for additional 
testing, and a treatment visit. To date, combining all of these efforts effectively 
has proven difficult in much of the developing world. 
Visual Inspection with Acetic Acid 
Visual inspection with acetic acid (VIA), also known as the acetic acid test (AAT) 
or direct visual inspection (DVI), is a low-technology method for cervical cancer 
screening. The process involves inserting a vaginal speculum to gain adequate 
visualization of the cervix and then swabbing the cervix with a 3-5% acetic acid 
solution (table vinegar) for one to three minutes prior to inspecting it (Carr and 
Sellors 2004). Normal, healthy squamous epithelial cells are pink. When 
increased nuclear proteins associated with dysplastic changes are present, the cells 
tum white, differentiating them from neighboring cells even to the naked eye. A 
trained examiner records results as negative (no acetowhite changes), positive 
( acetowhite changes present), or suspicious for cancer. Although acetowhite 
changes are not specific to cervical neoplasia, a well-trained provider can 
distinguish the differences between inflamed and regenerating epithelium and 
cervical neoplasia. When acetowhitening associated with neoplasia is found, 
treatment can be offered immediately to women with positive tests depending on 
the training of the provider, the equipment available and the patient's preferences. 
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Since the widespread adoption of Pap smears, VIA has not been broadly used as 
part of comprehensive cervical cancer screening programs. However, with the 
recent increase in interest in the divergent success of Paps in the developed and 
developing world, new work is being done to validate the true accuracy of VIA, 
especially in low-resource settings. The most complete examination of the 
accuracy of VIA is a qualitative summary of the literature published by Gaffikin, 
Lauterbach and Blumental in Obstetrical & Gynecological Survey in 2003. 
Authors searched for papers published from 1982 through 2002, resulting 16 
studies that met their criteria (primary data analysis, only VIA, and no 
magnification). Because most VIA pilot programs are being done in the 
developing world, most of the included studies were from low-resource settings. 
Much like the Nanda team's review of the accuracy of Paps, Gaffikin, Lauterbach 
and Blumenthal found significant variation, reporting sensitivity as 66-96% and 
specificity as 64-98%. They conclude, as do most of the studies and authors, that 
VIA's performance compares favorably to that of Pap smears, offering perhaps 
increased sensitivity (and certainly a narrower range) but decreased specificity. 
However, as Gaffikin notes, their review prompts further research. This review is 
not a rigorous, quantitative assessment or meta-analysis. The included studies 
suffered from significant biases, most importantly verification bias. Although the 
studies varied, most only verified the results of VIA with colposcopy when the 
woman had a positive test. Thus, the actual specificity is likely lower than 
reported, as some of the negative results are likely false negatives. The authors 
offer a generally positive assessment of VIA for early detection of cervical cancer 
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but call for quautitative studies aud meta-analyses of trials that do not suffer from 
verification bias or selection bias. 
Since this review, published data are now available from a massive (almost 
57,000 women) trial of VIA in India and Africa. In this trial, which was designed 
to determine the accuracy of VIA and VILI (visual inspection with Lugol's 
iodine, a technique similar to VIA), all women sequentially received each method, 
followed by colposcopy, aud biopsy when clinically appropriate. Each test was 
done independently and blindly. Across the 11 study sites, detection ofHSIL had 
a pooled sensitivity of76.8% (95% CI:74.2-79.4%), specificity of 85.5% (95% 
CI:85.2-85.8%), positive predictive value of9.4% (95% CI: 8.8-10.8%) aud 
negative predictive value of 99.5% (95% CI: 99.4-99.6%). These values are 
consistent with the ranges reported by Gaffikin' s team and demonstrate the 
relatively high specificity and negative predictive value of VIA but also the poor 
positive predictive value due to the low sensitivity. Because of the ability to offer 
immediate results and treatment, this high false positive rate is a concern to some, 
because healthy women will get unnecessarily treated. Claeys, DeVuyst and 
Gonzales (2003) compared relative false positive rates between Paps and VIA in 
Nicaragua aud expressed concerns about the effects of false positive rates on 
program planning and development of effective referral mechanisms. 
In an effort to shift toward effectiveness trials, Sankaranarayanan, Basu and 
Wesley (2004) recently released a paper from the only published, randomized trial 
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of VIA screening in the last 20 years. The trial included over 78,000 rural Indian 
women between the ages of30 and 59 who were randomized to either VIA 
screening or control (no screening). After screening, test positive women were 
counseled and offered colposcopy and punch biopsy, as necessary. They 
measured outcomes associated with program effectiveness - feasibility, 
participation rates, detection rates of CIN and invasive cancer, and program 
sensitivity to detect invasive cancer (calculated as the proportion of screen-
detected biopsy confirmed cancer cases among the total invasive cancer cases 
recorded during the follow-up in the intervention arm). Women with invasive 
cervical cancer were referred to local treatment facilities for staging and 
treatment. Researchers used a population-based cancer registry to collect 
information about cancer incidence and mortality. Mortality rates were also 
extracted from death registries. The program demonstrated a 71.1% sensitivity to 
detect invasive cancer. 
This trial is significant because it is the first randomized trial assessing a massive 
VIA screening program in low-resource settings. The study design does not allow 
for a better assessment of VIA accuracy. However, this trial does move in the 
right direction of assessing effectiveness. Although questions about acceptability 
and feasibility of VIA-based screening programs have already been positively 
answered in large, pilot programs in Thailand and Ghana, long-term effectiveness 
in terms of cervical cancer incidence and mortality are still not known. As the 
duration of some of these programs progresses, researchers will soon be able to 
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demonstrate whether VIA has any significant impact on cervical cancer incidence, 
morbidity and mortality. 
Aside from a current lack of effectiveness data, there are other concerns about 
VIA-based prevention efforts. By its very nature, VIA relies on visual inspection 
of the ecto- and endocervix. Because the endocervix abuts the transformation 
zone, an area that is at high risk for developing cervical cancer, visualization of 
this area is fundamental. In post-menopausal women, the transformation zone 
often begins to involute as the endocervix atrophies. Thus, although there is not 
quantitative evidence demonstrating the effect of this anatomic change on VIA's 
ability to detect cancer, specialists are rightfully concerned about its decreased 
applicability in postmenopausal women. Because glandular cancers (as opposed 
to the more common squamous cell cancers) are also more common in the 
endocervical canal, VIA is less adept at detecting them. (Sankaranaryanan, 
Gaffikin and Jacob 2005). 
Despite these concerns, if one considers only technical issues and ignores for a 
moment test efficacy and effectiveness, VIA is ideal for low-resource settings. 
The process requires no electricity, only a light source which can easily be 
provided by a battery-powered lamp or headlamp. Moreover, nurses, midwives 
and even lay health advisors can be trained to provide this screening procedure. 
Several internationally focused health organizations (PATH, JHPIEGO, IARC) 
that work to provide appropriate health resources and technologies to low-
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resource settings have developed manuals and protocols for training mid-level to 
lay health advisors in VIA. These programs, ranging form several days to two 
weeks, can be targeted to different levels of clinicians and include basic cervical 
anatomy, reference manuals, photographs and clinical practice. Use of these 
training protocols in several studies demonstrates their effectiveness in equipping 
health providers to perform this procedure. In Sankaranarayanan, Basu and 
Wesley's clinical trial reported above, eight nurses completed a three-week 
training course using IARC training manuals. A photograph-based assessment of 
their competency prior to beginning any clinical screening activities demonstrated 
that all providers could correctly assess over two-thirds of the photographs. In an 
effort to maintain clinical skills and improve effectiveness, trainees took refresher 
courses every 6 months. In Sankaranarayanan, Basu and Wesley's (2004) larger 
trial conducted in India and Africa, 51 female health workers took part in a five-
day intensive course based on IARC manuals and also got one to two day 
refresher courses throughout the study. Their colposcopy-confirmed detection 
rates suggest adequate competence levels as well. 
VIA also offers the benefit of immediate results and the possibility for immediate 
treatment, ifthe patient so desires. Often referred to as a "see and treat" approach, 
this method offers significant advantages in areas where women are traveling far 
to seek care aud may not return for follow-up. Moreover, it allows for provider 
education and counseling ofthe patient to ensure that she understands the results 
of her screening test. The treatments offered post-VIA, cryotherapy and LEEP, 
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are minimally invasive and pose minimal risk. However, they do require 
additional provider training, as well as access to a medical facility that is able to 
deal with rare but possible complications such as bleeding and infection. At a 
population level, the ability to offer immediate treatment is fundamental to 
alleviating the significant loss to follow-up that occurs for Pap-positive women, 
especially in rural parts of Honduras where access to care is quite limited 
However, at the individual level, the high false positive rate may lead to 
unnecessary treatment of healthy women. 
HPVVaccine 
With the discovery of HPV as a necessary causal factor for cervical cancer, 
researchers have begun to explore the possibility of an HPV vaccine as primary 
prevention of cervical cancer. Although therapeutic vaccines are also being 
explored, because we are most interested in cervical cancer prevention, I will 
focus only on prophylactic vaccines. The data in this area are all very new, and 
still incomplete. Prophylactic vaccines against HPV can be developed in many 
ways but are all dependent on somehow stimulating an immune system response. 
The most promising prophylactic vaccines are composed of virus-like particles 
(VLPs) but lack any harmful viral genome. They initiate an HPV type-specific 
neutralizing antibody response that prevents primary HPV infection. Because 
preventing primary HPV infection is the goal, vaccines must be administered 
prior to the onset of sexual activity. The vaccines developed to date involve three 
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doses at months zero, one, and six of an intramuscular injection and have been 
well tolerated with no report of serious adverse events. 
Vaccine trials are a work in progress, with new results in the pipeline and a 
significant part ofthe development process already underway. Phase I and II trials 
have already clearly established proof of principle, immunogenicity and safety 
(Lehtinen and Paavonen 2003; Tjalma, Arbyn and Paavonen 2004). Phase III 
trials, which demonstrate vaccine efficacy, are currently ongoing around the 
world. The first phase III trial, completed in 2002, was a placebo controlled trial 
of an HPV16 VLP vaccine. With an average of two years of follow-up, the 
vaccine was 91% effective at protecting against infection with HPV16 and 100% 
effective against persistent HPV16 infection. This trial paved the way for Phase 
III trials of a combined vaccine. This May, Harper, Franco and Wheeler (2005) 
published pilot results from an efficacy trial of a combined HPV16!18 L1 VLP 
vaccine. In this double-blind, multi-center, randomized trial in North America and 
Brazil, over 1,000 HPV-negative women aged 15 to 25 received either three does 
of the vaccine or placebo. Protection from persistent HPV 16118 infection was 
100%. The bivalent vaccine was also 92.9% effective at preventing cytologic 
abnormalities. This data represents the best information we have to date on 
vaccine effectiveness. 
Clearly, these results need to be replicated in large, Phase III and Phase IV trials 
with much longer follow-up. The two main contenders to produce such results are 
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Merck's quadrivalent HPV6/11116/18 VLP vaccine and Glaxo-SmithKiine's 
bivalent HPV16/18 vaccine. Both companies are initiating large, multi-center 
trials in Europe, North America, Latin America and Asia over a forty-eight month 
period. Despite the longer follow-up times compared to previous trials, endpoints 
will still be intermediate and will include protection against persistent HPV 16 
and HPV18, not incidence and mortality. Unfortunately, the long pre-invasive 
period for cervical cancer means that even well-designed trials will not be able to 
produce mortality endpoints for at least ten more years. 
Although vaccine development has been very promising so far, there are still 
significant areas of uncertainty. The specificity of viral capsid proteins requires 
that VLP vaccines need to be targeted to the specific virus type. Initial 
development has been targeted at the most common types, specifically HPV16 
and HPV18. Geographic variation in type prevalence will determine the relative 
effectiveness of a combined HPV16/18 vaccine in different parts of the world. In 
Honduras, HPV16 or HPV18 is found in 51.9% of cases of invasive cervical 
cancer (Ferrera, Velema and Figueroa 1999), so even a bivalent vaccine could 
prevent only about half of all cancer cases. 
Aside from issues of vaccine HPV type make-up, we still do not have complete 
evidence about the existence of cross-reactivity between strains. A qualitative 
review published in 2003 concluded that cross-reactivity is very rare, but cited no 
primary or secondary data to justify that claim. Two more recent reviews cite 
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prospective data suggesting cross-reactive inununity to non-vaccine types (Bell 
and Alvarez 2005; Lehtinen and Paavonen 2003). Clearly, this issue is not yet 
fully understood, and perhaps will not be until vaccines have been widely used for 
at least ten years. Viral variation to develop vaccine resistance is also possible. 
Forttmately, HPV is a biologically stable virus that is thought to have remained 
the same for over 200,000 years (Lehtinen and Paavonen 2003), perhaps 
decreasing the chance that it will alter itself in response to new host immunity. 
We must also remain concerned about breakthrough infection, or infections by 
strains that were previously not oncogenic but become so to occupy a niche in 
response to vaccine-induced reductions of currently oncogenic types. Long-term 
monitoring ofHPV type present in CIN and invasive cancers will be the only way 
to answer that question. 
We still have numerous other unanswered questions about HPV vaccines. For 
example, although antibody titers post-vaccination have been substantially higher 
than those measured after infection, we do not know how long this immunity will 
last. Initial inununity is established in three doses, but it is possible that a booster 
dose will be required to maintain long-term protection. Some researchers are also 
considering whether different delivery methods (oral or via the nasal mucosa) 
could invoke levels of both systemic and cervical mucosal response similar to that 
of an intramuscular injection with just one dose (Tjalma, Arbyn and Paavonen 
2004). Although this could possibly simplify vaccine program implementation, 
we still do not know if this will be possible. As with any vaccine, even with 
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incomplete coverage, unvaccinated persons might benefit somewhat from herd 
immunity. Even so, the heterogeneity ofHPV types means that even with a 
completely effective vaccine and 100% coverage, there will still be sporadic cases 
of cervical cancer. Tjalma, Arbyn and Paavonen (2004) estimate that even 
complete coverage with a highly effective multivalent vaccine that combines the 
eight most common oncogenic HPV types could only prevent 95% of cervical 
cancers. Thus, even with an ideal vaccine, some type of screening will still be 
necessary. 
Study Design and Methods 
A policy analysis of a public health question requires a wide range of data sources 
to assess accurately the clinical and epidemiologic ramifications of cervical 
cancer screening and to place them within their appropriate social and political 
framework. This work combines the strengths of what have traditionally been 
defined as both quantitative and qualitative research by relying on the underlying 
"logic of inference" inherent in both (King, Keohane and Verba 1994). Clearly, to 
conduct such an analysis adequately is a massive undertaking and thus, I have 
tried to stay focused on the main question of determining the most appropriate 
screening modality. In this effort, I have used three main data sources: (I) a 
systematic review of the published literature, as well as archival and aggregate 
health and health services data, (2) personal field notes, and (3) key informant 
interviews. Combining these different sources will allow for triangulation of my 
methods, resulting in the most complete analysis possible. Using this information, 
I will apply a set of six evaluation criteria- efficacy, effectiveness, cost, equity, 
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acceptability and feasibility~ to make final recommendations about the most 
appropriate screening method and prevention program in this setting. 
Data Sources 
I performed a systematic review of the published literature on cervical cancer 
incidence, screening, and prevention using standard databases such as MedLine, 
as well as within the publications of relevant organizations such as ACCP, FIGO 
(International Federation of Gynecologists and Obstetricians), PAHO and the 
WHO. My MedLine search included the terms cervical cancer, screening, 
prevention, accuracy, Papanicolau, VIA, DVI, see and treat, HPV vaccine, 
developing, low-resource, and Honduras. The search, which generated over one 
hundred articles, was generally restricted to those published in English, after 
2000. To narrow the search, I focused on those articles most pertinent to the 
developing world, and to Honduras specifically. When they were available, I used 
randomized controlled trials, systematic reviews and meta-analyses as opposed to 
cohort and case control trials. Most of my analysis focused on approximately 
thirty ofthe most recent and methodologically sound articles generated from this 
search. 
For information regarding Honduras' health care system, as well as broader 
questions of acceptability and feasibility, I consulted social science databases 
such as JStor, Web of Science and Central American search engines, as well as 
publications from relevant organizations such as the World Bauk, PAHO and 
WHO. This search included the same terms used for the MedLine search, with 
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the exception of accuracy, and also included the terms acceptability, feasibility, 
implementation, health care policy. This search was limited to English and 
Spanish-language articles. In addition, I sought source recommendations from a 
Central American politics expert at UNC-Chapel Hill and reviewed my own 
personal files. 
Aside from using published information, whether in peer-reviewedjoumals or 
government or NGO documents, I made a significant attempt to place information 
within the appropriate context through the use of field notes and key informant 
interviews. My field notes come from two separate trips to Honduras, one during 
the planning stages of the community-based health education program I have 
referred to earlier, and one during implementation of the inaugural year of the 
program. In planning and carrying out this program, I have had significant contact 
with key public and private sector health care providers and program planners 
who are collaborating with us on this project. Moreover, through time spent doing 
educational workshops with women, providing clinical services, and living with 
families, I have also developed a keen understanding of the health knowledge 
base, concerns and desires of women living in southern Honduras. 
To address some of my specific policy questions more systematically and directly, 
I also conducted in-depth, open-ended interviews with four key informants who 
represent different domains within the Honduran health care system. (Please see 
Appendix A for a sample of the survey instrument in English.) Although my 
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initial goal was to contact a known informant from each of four key sectors in 
cervical cancer prevention policy (national government sector; provider/clinician; 
research/academic; non-governmental organization/community-based 
organization), logistical difficulties with telephone and email communications to 
Honduras made this almost impossible. I have, nonetheless been able to obtain 
information, in person, by phone, and over email, from the following key 
informants who represent the same or similar key sectors of cervical cancer 
prevention policy: 
Sector Level Position 
Government Regional Zona 4 Director; Ministry of Health* 
Clinical Care Provision National Chief of Division of Research, 
Evaluation & Statistics; AHONPLAF A 
Non-Governmental Local Director; Communidades Unidas 
Organization/Community-
Based Organization 
International Health International Project Manager for Non-
Organization Communicable Diseases; PAHO 
*Th1s mformant d1scussed the survey w1th the gynecolog1sts who work at the mam pub he hospltalm h1s reg10n. Thus, 
although his responses are taken to be the official MoH position on these issues, they arc also reflective oft he vie\VS of 
public sector gynecologists. 
Each of these leaders offers a unique perspective on the Honduran health care 
system and on cervical cancer prevention policy in particular. 
Even with the constraints imposed by language difficulties and technical 
obstacles, I have gained an indispensable third data source by conducting these 
survey interviews. The survey, designed to elicit in-depth responses from 
informants, consists of open-ended questions focusing in large part on 
acceptability and feasibility (political and economic) of each of the three policy 
alternatives. I wrote the surveys, as well as the initial email contact messages with 
41 
which they were introduced, in English and translated them into Spanish. They 
were then reviewed and corrected by a native Spanish speaker. After translating 
my notes from telephone interviews or written survey responses received via 
email, I used both content and textual analytical techniques to analyze the open-
ended responses, following established methodological principles. I compared 
similarities and differences in response patterns, and searched the responses for 
the emergence of particular themes or perspectives to guide my analysis. 
Evaluation Criteria 
I have used conventional techniques of policy analysis, and more specifically 
those for assessment of prevention programs, to evaluate each screening method 
based on the following six criteria: efficacy; effectiveness; cost-effectiveness; 
equity; acceptability; and feasibility. I will briefly describe the working definition 
of each ofthese terms as I used them in the analysis, noting when primary and 
secondary prevention methods required different definitions: 
Efficacy 
Efficacy is generally taken to mean the performance of a test or intervention 
under ideal circumstances, i.e. can it work? Efficacy trials test whether the 
intervention can have the intended effect. In many cases, efficacy represents the 
immediate impact of a test or procedure, often an intermediate step that is 
divorced from its broader clinical implication. Thus, in the case of Pap smears and 
VIA, efficacy will be defined as the test's accuracy, as measured by its sensitivity 
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and specificity in detecting abnormal cells (CIN or cancer). For HPV vaccines, 
efficacy will be defined as vaccine's ability to prevent persistent HPV infection. 
Due to the long delay period in generating data regarding prevention of cervical 
cancer, vaccine trials are currently only reporting a vaccine's ability to prevent 
primary and persistent HPV infection. However, this is not sufficient for 
demonstrating the true accuracy of vaccines. A recent WHO consensus 
conference determined prevention ofHPV infection was not an adequate efficacy 
endpoint for use in program planning because although infection with high-risk 
type HPV is a powerful predictor for high-grade dysplasia or cancer, there is sill 
no formal evidence demonstrating that preventing persistent HPV infections has 
an impact on cervical cancer development (Pagliusi and Teresa Aguado 2004). 
Effectiveness 
Effectiveness is generally taken to mean the performance of a test or intervention 
in real life settings, e.g. does it work? (Fletcher, Fletcher and Wagner 1996). 
Effectiveness trials weigh both the harms and benefits of interventions. More 
broadly, effectiveness demonstrates an intervention's ability to meet broader 
clinical or public health goals, such as decreasing the incidence or mortality from 
cervical cancer. Thus, in this situation, for all of the policy alternatives, 
effectiveness will be defined as success in decreasing cervical cancer incidence 
and mortality in a real-world, Honduran setting. 
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Cost-effectiveness 
Although cost-effectiveness analyses are driven by assumptions about the 
monetary value of situations that are hard to quantify accurately (death, health, 
years oflife lost (YLL), etc.), they are still useful tools in policy analysis for 
comparing alternatives and determining the economic cost or benefit of a specific 
prevention program. Cost-effectiveness data specific to Honduras for each of the 
three policy alternatives are not currently available. Thus, I will review the cost-
effectiveness studies that have been published and make recommendations based 
on their applicability to this discussion using a combination of outcomes. 
Equity 
An equity-focused criterion allows me to assess how fairly each prevention 
strategy can be implemented and to determine who will benefit most and least 
from it. Sociodemographic forces in Honduras, and access to services, both 
financial and geographic, are the main determinants of who benefits. Thus, I will 
compare these policy alternatives as they apply to low-resource versus high-
resource women, and urban versus mral women. 
Acceptability 
Acceptability is defined as the policy's acceptability to Honduran women and 
health care providers. Again, very few Honduran data exist. Work in other 
developing countries, as well as key informant reports and field notes, will guide 
this analysis. 
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Feasibility 
Feasibility is a broad term intended to indicate whether or not a program could be 
implemented effectively. In this case, I will operationalize feasibility as key 
informants' assessments of the political, economic and social constraints that may 
hinder prevention policy implementation. 
Evaluation 
Based on the definitions for evaluation criteria described above, I have analyzed 
each of the three prevention methods. When quantitative analysis is possible, such 
as comparing efficacy, effectiveness, and cost-effectiveness, I have used numbers 
to make a final evaluation. With the more qualitative criteria of equity, 
acceptability and feasibility, I have used the current MoH Pap-based program as 
the baseline and have determined whether the other two methods, if implemented, 
would be stronger or weaker along the same criterion. Based on the aggregate of 
these evaluations, I have made final recommendations about the most appropriate 
prevention strategy to be pursued in Honduras at this time. 
Efficacy 
Pap Smears 
Best estimates of Pap accuracy based on recent reviews report a sensitivity of 
30% to 87% and specificity of 86% to 100% (Nanda, McCrory and Myers 2000). 
However, using studies conducted in developing countries, Pap accuracy is 
somewhat lower, with sensitivity ranging from 44% to 78% and specificity 
ranging from 91% to 96% (Sankaranaryanan, Gaffikin and Jacob 2005). My 
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P AHO informant, as well as data from low-resource settings, both suggest that 
this discrepancy is due to sampling inadequacies (on the part of the examining 
provider) and reading errors (because of poor laboratory equipment or inadequate 
training of cytotechnians). 
This same informant also reports the phenomena of many slides returning with the 
result of"injlamaci6n" (inflammation). This is an indeterminate result, likely 
associated with some sort of change in the normal vaginal flora that obscures the 
true efficacy of the Pap in detecting pre-cancerous cells. We experienced this 
problem frequently while working in Honduras. Many women were upset and 
confused by this result, focusing on it and any possible ramifications for sexually 
transmitted infections, instead of the main focus of Pap smears, cancer detection. 
It is unclear whether the high preponderance of this result is due to reading errors 
or actually reflects a true state of increased levels of gynecologic inflammation in 
these women. We can say with certainty that it obscures the clarity of Pap results 
and calls into question the test efficacy. 
VIA 
The most comprehensive review of VIA accuracy reports sensitivity ranging from 
66% to 96% and specificity ranging from 64% to 98% (Gaffikin, Lauterbach and 
Blumenthal2003). Despite sensitivity that is generally higher than that published 
for Paps, several of my MoH informants as well as public sector gynecologists 
expressed concerns about the accuracy of VIA, mainly the low sensitivity and 
high false positive rate. Contrary to their concerns, other informants who have 
helped with the implementation of pilot programs in El Salvador and other 
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Central American countries report program specific sensitivity and specificity 
rates higher thau that of Paps, aud these informants therefore recommend VIA as 
an efficacious alternative. 
HPV Vaccine 
So far, data from vaccine trials suggest that vaccines are very efficacious at 
preventing persistent HPV infection. In the most recent report of a bivalent 
(HPV16/HPV18) vaccine, Tjalma, Arbyn and Paavonen (2005) reported 100% 
efficacy for protecting vaccinated women against persistent HPV16 and/or 
HPV18. 
Effectiveness 
Pap Smears 
Despite their widespread use, we do not know the true effectiveness of Pap 
smears in preventing cervical cancer. Laara, Day and Hakama ( 1987) reported 8-
73% decreases in mortality in five Nordic countries after implementation of 
national Pap-based screening programs. Models in the United Kingdom suggest 
that 80% of cervical cancer deaths have been prevented due to their national, Pap-
based screening program (Peto, Gilham and Fletcher 2004). 
Although these decreases are impressive, similar results have never been 
achieved, either empirically or anecdotally, in any developing country. According 
to the Alliance for Cervical Caucer Prevention, cervical cancer screening 
programs in developing countries have had "little or no impact on cervical cancer 
mortality rates" (ACCP 2004). Although mortality from cervical cancer in 
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Honduras appeared to drop from 40.4 per 100,000 women in 1990 to 36.9 per 
100,000 in 1999, in 2002, the rate was estimated to be back up to 40 per 100,000 
(MoH 2004). Thus, despite over twenty years of a national prevention program, 
there has been no significant change in mortality rates and they are still very high, 
even in relation to other parts of the developing world. 
VIA 
Despite accnracy and efficacy fairly comparable to those of Pap smears, VIA has 
not been used in widespread prevention efforts for long enough to generate 
effectiveness data. Ongoing trials are moving in this direction, but data will not be 
available for as much as a decade. Direct evidence does not currently exist, but 
models have been developed to help policy makers and program planners develop 
more effective prevention programs for low-resource settings. In the most 
comprehensive of these models, Goldie, Kuhn and Denny (2001) used a 
mathematical model based on the natural history ofHPV infection and cervical 
cancer to generate clinical and cost-effectiveness outcomes. Based on their model, 
once in a lifetime screening at the age of35 with VIA followed by cryotherapy (a 
one-visit approach) could result in a 26% reduction in cervical cancer incidence. 
This was compared to Pap screening (as a two-visit strategy) once in a lifetime at 
the age of 35, which resulted in a 17% reduction in cervical cancer incidence. 
Although this model suggests that VIA offers a distinct benefit over Paps, this 
model is built around nnmerous assumptions that do not apply to Hondnras. The 
model is based on a population of previously nnscreened South African women 
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whose HIV infection rate is assumed to be approximately 8%. In Honduras, over 
60% of sexually active women between the ages of 15 and 49 report having ever 
been screened for cervical cancer (Secretaria de Salud 2002) . Moreover, at the 
end of 1999, the HIV/AIDS rate in Honduras was 1.9% (USAID 2000), 
approximately one fourth of the rate used in the South Africa model. The lack of 
prior screening and higher HIV rate suggest that any screening in this population 
would appear to perform much better than in the Honduran population. Although 
this is unlikely to vary the relative performance of each method, the absolute 
benefit is probably lower in Honduras. However, this analysis still suggests that 
the relative effectiveness of VIA is superior to that of Paps. 
A second model to assess the clinical and cost effectiveness of different 
prevention strategies found similar results (Mandelblatt, Lawrence and Gaffikin 
2002). This model compared the costs and benefits of various screening strategies 
based on a population-based simulation model developed in Thailand. In this 
model, a Pap smear every five years in women aged 35 to 55 resulted in a 13.5% 
predicted reduction in invasive cervical cancer. VIA, performed every five years 
on 35 to 55 year old women resulted in a 34.9% predicted reduction in invasive 
cervical cancer. Thailand's rural population and HIV/AIDS rate of 1.5% 
(UN AIDS 2004) much more closely approximate that of Honduras. As with 
Goldie, Kuhn and Denny's model, it is unreasonable to assume that this exact 
same level of effectiveness would be gained in Honduras. It is unlikely, however, 
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that the relative superiority of VIA over Pap would be significantly altered if the 
model were changed to reflect Honduran population dynamics. 
HPV Vaccine 
Because vaccine development is still a work in progress, effectiveness data are 
also a result of modeling at this time. Several models have been developed over 
the past three years to estimate the clinical and cost-effectiveness of vaccinations. 
Using a mathematical model based on disease progression, Hughes, Garnett and 
Koutsky (2002) estimated that a 47% reduction in invasive cervical cancer 
incidence could be achieved by a bivalent (HPV 16118) vaccine. The model 
assumes 95% coverage with a bivalent vaccine that is 75% effective and confers 
ten-year immunity. 
A separate model developed by Kulasingam and Myers (2003) compared 
reductions in cervical cancer incidence and mortality between no screening, 
screening only (Pap), vaccine only and vaccine with screening at different 
intervals. Although Pap screening alone every three years was estimated to 
decrease incidence and mortality by 72.8% and 83.0% respectively, vaccine alone 
was only predicted to result in 16.8% and 17.7% decreases in incidence and 
mortality. If triennial screening is added to vaccines, incidence and mortality 
decrease by 74.3% and 83.5% respectively. The vaccine assumptions in this 
model were fairly similar to those used by Hughes, Garnett and Koutsky and 
assumed I 00% coverage with a vaccine that covers 70% of oncogenic types and 
is 90% effective at conferring ten-year immunity. 
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The fairly significant differences predicted by these models raise two concerns. 
First, one cannot be certain how much ofthis discrepancy is dependent on the 
differing assumptions made in these models, and which is more closely reflective 
of Honduran reality. Second, aside from pointing out the weakness of such 
models, this discrepancy also highlights the fact that the true impact of a possible 
vaccine is not yet known. With these uncertainties, even once vaccines are ready 
for widespread implementation, they will not be a stand-alone strategy but will 
have to be combined with some form of secondary screening. 
Cost-effectiveness 
Pap Smears 
Without better access to MoH officials and government documents, it is difficult 
to determine the true cost-effectiveness of Honduras' Pap-based prevention 
efforts. Lacking additional data, it is simple to argue that, since the mortality from 
cervical cancer has remained basically unchanged since 1990 (one year prior to 
the implementation of the prevention program) to 2002 (MoH 2004), the program 
has not been cost-effective. In fact, the program may have been quite ineffective, 
spending limited resources with no discernible effect on mortality. Although it is 
quite possible that the program's educational component has been beneficial, at 
least in rural areas, even these gains have not been documented to my know ledge. 
In the absence of more detailed cost data from the government, I have compared 
the relative cost-effectiveness of each of these prevention efforts based on several 
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recently published mathematical models referred to above in the effectiveness 
discussion. Although the assumptions iu these models, as discussed above, do not 
perfectly fit the Honduran context, the relative ranking of cost-effectiveness 
between strategies is unlikely to change, even when applied to Honduras. 
In the Goldie, Kuhn and Denny model, Pap screening cost-effectiveness was 
always dominated by other strategies, meaning it was less cost-effective relative 
to VIA and HPV DNA testing. In Mandelblatt, Lawrence and Gaffikin's model, 
Pap screening every five years for women aged 35 to 55 had an incremental cost 
effectiveness ratio (US$/life years) almost six times greater than that of VIA. 
Despite any flaws in the model, it seems unlikely that a six-fold difference would 
be overcome, suggesting that, in low-resource settings such as Thailand and 
Honduras, Paps are not the most cost -effective method for preventing cervical 
cancer. This idea was reiterated at the patient level by my NGO informant. She 
suggests that costs are one of the three main reasons that the Pap-based program 
has not been effective in Honduras. 
VIA 
As with VIA effectiveness, I have made cost-effectiveness comparisons based on 
models since no Honduran VIA programs exist.4 By comparing the relative cost-
effectiveness of each of these prevention efforts based on the same recently 
-1- According to my MoHand PAHO respondents, VIA is not currently in use in Honduras. 
However, my NGO representative reported that when she went to her gynecologist in April 2005 
for a Pap smear, she was given the option of VIA. Her gynecologist told her that VIA is being 
used in Honduras at a lower cost to the patient and with immediate results. However, my 
informant reports that its use is not widespread and that most women do not have access to a 
provider who does it. 
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published mathematical models referred to above, I can draw conclusions about 
the three methods under consideration in this discussion. As discussed above, 
although the assumptions in these models do not perfectly fit the Honduran 
context, the relative ranking of cost-effectiveness between strategies is unlikely to 
change, even when applied to Honduras and provides a framework for research 
when such data do become availab !e. 
In the Goldie, Kuhn and Denny model, VIA screening was the only strategy that 
was found to be cost-saving. A single, lifetime VIA screen followed with 
cryotherapy as necessary was more effective and less costly than no screening at 
all. Increasing the number of times a woman is screened, up to every five years, 
decreased the cost effectiveness, but it still remained more cost-effective than 
other strategies. In Mandel blatt, Lawrence and Gaffikin's model, VIA followed 
by cryotherapy as needed every five years for women aged 35 to 55 had an 
incremental cost effectiveness ratio (US$/life years) of$263, several-fold lower 
than the next most cost-effective method. To put these costs in perspective, a 
program based on these guidelines with 100% coverage would cost an extra $0.79 
per Thai woman. That would increase the per capita health expenditures in 
Thailand by 0.08%. Thailand currently spends $112 per capita. This lies within 
the $49 to $165 range of that reportedly spent by Honduras per capita (The 
Economist Intelligence Unit 2004). Thus, even with all of the cost and 
demographic differences that likely exist between these two countries and 
53 
therefore alter the model, the relative size of such an investment is likely to be 
very small, even when applied to Honduras. 
HPV Vaccine 
Unfortunately, none of the models developed to date compare all three of the 
methods under discussion here. Most of the vaccine-relevant models compare 
vaccines to Paps alone or to a combination of the two, since early vaccine-based 
prevention programs will require Pap screening (or some other secondary 
prevention method) at least until long-term effectiveness data are available on 
vaccines. Kulasingam's and Myers' model (2003) fotmd that a vaccine alone was 
not cost-effective in terms of incremental cost per life-year saved. In their model, 
Pap screening every five years had an incremental cost-effectiveness ratio of 
$6,030 per life-year saved. The two methods combined were also not found to be 
cost-effective. Although the cost figures generated were based on a hypothetical 
cohort of American women and the associated health care costs in the United 
States, the cost of the vaccine is listed as $200. This is based on an Institute of 
Medicine report that estimated the cost of a full course (three doses) ofthe 
vaccine as well as all associated direct costs. Although the direct costs are 
certainly higher in the US than in Honduras, even one half of the $200 amount is 
within the range of the entire per capita annual expenditures on health care 
services for Honduras (The Economist Intelligence Unit 2004), suggesting the 
vaccine is cost-prohibitive at this time. 
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Although other models like that of Goldie, Kohli and Grima (2004) may be useful 
in the long term in helping developed countries determine the most cost-effective 
way to add vaccines to their Pap-based screening programs (such as at what age 
they should initiate screening, or at what interval they should recommend 
secondary screening tests), their results are simply not relevant to a low-resource 
setting like Honduras. The lowest incremental cost-effectiveness ratio reported is 
$12,300 per quality-adjusted life year for combining a 100% effective vaccine 
with conventional cytology screening every five years, starting at the age of 35. 
This model serves to reiterate the relatively high cost of vaccine-based prevention, 
at least based on current projections, and the impracticality of considering such an 
intervention in a low-resource setting at current cost levels. 
These models reiterate the views expressed by several of my key informants. 
Although my P AHO informant reported that most Latin American countries are 
"well-positioned" to start vaccines as soon as they are available, she agrees that 
they are currently cost-prohibitive. She repeated cost estimates of$35 to $50 per 
dose, making the vaccine much more expensive that of current Pap-based efforts, 
while not eliminating the concurrent need for them, driving costs up even further. 
Equity 
Pap Smears 
Honduras' current Pap-based prevention program is not completely equitable. 
Although they did not address the problem in terms of equity, all informants 
thought that low coverage, especially in rural areas, was part of the problem with 
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current prevention efforts. The most recent national health survey, published in 
2002, shows that rural, poor and less educated women have lower rates of Pap 
coverage than urban, wealthy and more educated women. Nationally, among 
women aged 15 to 49, 69.5% of urban women and 52.6% of rural women have 
ever had a Pap smear. Tn the two major urban centers, where services are most 
accessible, 86.3% (Tegucigalpa) and 65.1% (San Pedro Sula) of 15 to 49 year old 
women have ever gotten a Pap smear. Rural women are more likely to get Pap 
smears at public medical facilities (MoH facilities), and a fourth of them report 
not knowing the results of their Pap smears. My work in southern Honduras 
suggests that this number is actually much higher, and that the women who do 
receive their results often do not understand what they mean. MoH facilities are 
unfortunately quite slow at getting results back to women. Although the 
"Strengthening Project" has led to some improvement in this area, in 2001, 58.6% 
of women who got Pap smears at MoH facilities reported waiting 21 days or 
longer to get their results. 
Differences in Pap rates are evident across income and educational levels as well. 
Of women aged 15 to 49 years with no education, only 42.6% have gotten a Pap 
smear in the past year and 27.5% of them do not know what the results were. 
Among similarly aged women with greater than a high school education, 62.6% 
have gotten a Pap smear in the past year and only 6.9% do not know what the 
results were. Among low-income women, only 46.1% have gotten a Pap smear in 
the past year, with 31.4% not knowing the results, as opposed to 58.1% of high 
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income women getting Paps in the past year and only 7.8% not knowing the 
results. Based on these national statistics, it seems fairly safe to say that although 
Pap services are accessible throughout the country, the current prevention 
program disproportionately benefits urban over mral women and wealthy, 
educated women over poor, less educated women. 
VIA 
Improved equity is one of the major strengths of a VIA-based cancer prevention 
program. Because nurses and LHAs can be trained to provide screening services, 
mral health centers with no physician coverage could provide these services. 
Thus, mral women would have much better access to preventive care. Moreover, 
because results are immediately available, women, both urban and mral, will not 
only receive their results but also counseling to ensure that they understand them 
and any need for follow-up. The ability to offer on-site results with counseling 
will also be of great benefit to less educated women who currently are less likely 
to know the results of their last Pap smear. Thus, a VIA-based program offers the 
distinct possibility of more equitably benefiting all women across geographic, 
education and income boundaries. 
HPV Vaccine 
Much like a VIA-based programs, a vaccine-based prevention program can make 
use of nurses and LHAs to provide primary prevention care, allowing for much 
broader geographic coverage of services. The ability to broaden the service 
delivery area and thereby decrease urban/mral differences in access to care is 
well-demonstrated by the childhood immunization program. Across all five 
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childhood vaccinations, less than one percentage point of difference exists 
between rates of urban and rural children who have received their vaccinations 
(Secretaria de Salud 2002). Broader access to services also diminishes the 
differences in utilization based on educational levels, with a difference ofless 
than 5% in immunization rates for children of less- versus well-educated parents 
(Secretaria de Salud 2002). Information is not available for rates based on 
parents' income. Although increased access to vaccination services could help in 
prevention, the required, associated Pap smear services would likely suffer from 
the same access issues as a stand alone Pap-based program. Thus, although 
vaccine coverage would improve equity, the full benefits of the prevention 
program would still not be equally enjoyed by rural, less-educated and less 
wealthy women. 
Acceptability 
Pap Smears 
In 2002, 60.9% of sexually active women aged 15 to 49 reported ever having had 
a Pap smear (Secretaria de Salud 2002). Their relatively high levels of compliance 
to recommended Pap screening recommendations suggest that Honduran women 
are fairly accepting of the current, Pap-based prevention program. Anecdotally, 
many women are uncomfortable with the sensitive nature of a screening visit but 
do it anyway because they recognize its importance. Although some young 
women may not get screened because such a clinic visit implies a degree of sexual 
activity that is not publicly permissible (Linthicum 2004), these are not the 
women who are at highest risk for development of cancer. 
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VIA 
Because VIA is not currently used widely in Honduras, determining the 
acceptability of a see-and-treat model is largely dependent on the effectiveness of 
cryotherapy, key informant feedback and acceptability data generated from see-
and-treat model programs in other developing countries. As already briefly 
discussed, cryotherapy is a low-tech, minimally invasive method for offering 
immediate treatment to women with positive VIA results. Even when performed 
by non-physicians, cure rate ranges from 88% to 99% for pre-invasive lesions, 
which is consistent with that found for other methods (Mandelblatt, Lawrence and 
Gaffikin 2002). Aside from being effective, cryotherapy has a very low 
complication rate. In Thailand, where a single-visit approach demonstration 
project was recently implemented, over 600 women were offered immediate 
treatment with cryotherapy. Of the 98.5% who consented to immediate treatment 
(suggesting it is also very acceptable to women), none experienced major 
complications and only 4.4% returned for perceived, minor problems such as 
vaginal discharge and cramping. (Royal Thai College of Obstetricians and 
Gynaecologists (RTCOG), CCJHPIEGO Corporation for Cervical Cancer 
Prevention Group 2003). 
A similar but much larger single visit prevention program in Thailand also 
reported very high acceptability (Royal Thai College of Obstetricians and 
Gynaecologists (RTCOG), CCJHPIEGO Corporation Cervical Cancer Prevention 
Group 2003). Of the 5,146 women who had negative VIA results, 99.8% said they 
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would recommend the procedure. Ofthe VIA positive women who opted to have 
immediate cryotherapy, 97.5% said they would recommend both. Three months 
after their initial screening, 97.9% had recommended VIA to others and 94.5% 
said cryotherapy either met or exceeded their expectations. Because screening 
rates in this mral part of Thailand are very low, most ofthese women have likely 
never had a Pap smear. Thus, although their reported experience with VIA is very 
positive, we do not necessarily know that they would be any more or less 
accepting of Paps or an HPV vaccine. Two other very large trials of VIA accuracy 
in South India (>48,000 women) and Africa and India (~57,000 women) reported 
no recmitment issues, suggesting women in these areas are not resistant to VIA as 
a screening method. 
These model programs suggest that, even across cultural differences, women are 
accepting of VIA. More applicable to this analysis is the feedback I received from 
key informants. El Salvador, which is reasonably similar to Honduras both 
socially and culturally, has had several, large-scale see-and-treat programs 
successfi.1lly implemented by PAHO without any problems with acceptability. 
Women have embraced the program and seem to appreciate the convenience of 
being able to receive treatment immediately. My clinical care provision 
informant, who oversees research and programming for the main private sector 
provider of Paps in Honduras, expected similar results. She thought that 
Honduran women would readily accept a VIA-based approach, assuming it was 
tied to an education program. With the right information about what VIA is and 
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how it can be important in the early detection of cervical cancer, she believes 
Honduran women will accept it. 
Providers, however, have presented much greater concerns. Gynecologists have 
major uncertainty about the appropriateness of VIA and cryotherapy. These same 
P AHO programs in El Salvador that were so quickly accepted by women faced 
numerous barriers to initial implementation due to strong resistance from 
practitioners. VIA with immediate cryotherapy presents a whole new model for 
treating cervical dysplasia in the primary care setting. Similar concerns were 
voiced by my MoH informant, who talked to his gynecology colleagues at one of 
the major regional hospitals before responding to my survey. He reported their 
insistence that VIA is simply not an acceptable method due to the high false 
positive rate, without challenging their position. Although these gynecologists 
appreciate the advantage of being able to give women results immediately, they 
do not see it as outweighing the increased treatment of healthy women. This is of 
significant concern to them because cryotherapy is not currently practiced by 
most gynecologists. Thus a woman with a positive test would be referred to a 
specialist to receive a much more invasive procedure, such as conization,5 or even 
hysterectomy if she is past her childbearing years. In this context, a high false 
positive rate is quite concerning. 
5 Conization involves the removal of a cone shaped sample of cervix from the transformation zone 
for diagnostic as well as therapeutic purposes. The procedure is typically performed under 
anesthesia with a scalpel, laser or electrosurgery. Immediate and long-term complications include 
bleeding, infection, uterine perforation, cervical stenosis, and pregnancy-related difficulties. 
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A see-and-treat approach challenges several of the common practices and beliefs 
of gynecologists. Gynecologists are trained as surgeons. Shifting treatment of 
cervical cancer to a primary care setting requires a significant shift in mindset for 
gynecologists, who are much more schooled in invasive but more definitive 
approaches to treatment, such as cervical conization and hysterectomy. Moreover, 
allowing nurses and LHAs to offer not only preventive services but also 
therapeutic care represents a significant shift of control down the medical 
hierarchy and will require a major acquiescence by gynecologists. 
Although some of these barriers are specific to this field, there is a significant 
body of literature that details the challenges in disseminating and implementing 
innovations in medical care. Timely adoption of new practices is most effective if 
the innovation is evidence-based, well-perceived, and if the adopting institution 
supports "innovators" and "early adopters", or physicians who are willing to 
accept changes (Berwick 2003). In the circumstance of using a see-and-treat 
approach to cervical cancer prevention in Honduras, the MoH could go far in 
initiating this innovation. By improving the perception of the practice by 
disseminating more evidence about its effectiveness in low-resource settings, the 
MoH could facilitate implementation by innovators and early adopters. Only with 
this institutional support will this type of approach, which offers the advantage of 
immediate results and treatment, become a fundamental part of an improved 
prevention policy. 
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HPV Vaccine 
Determining the acceptability of an HPV vaccine in Honduras is quite difficult 
since they have not been implemented anywhere outside of clinical trials. Based 
on the high immunization rates of children, with approximately 89.2% of all five-
year old children being fully immunized (Secretaria de Salud 2002), we can 
surmise that, in concept, Hondurans are accepting of vaccinations. One of my 
informants reiterated this idea, suggesting that Honduran women are very 
cognizant of the importance of immunizations in preventing disease and would 
adopt this attitude for and HPV vaccine as well. 
However, vaccination for a sexually transmitted infection that may result in 
cancer is a much more complicated and culturally challenging concept that may 
not benefit from the same high levels of acceptance. Moreover, to be effective, the 
vaccine will need to be offered to girls, and possibly boys, before the onset of 
sexual activity. Due in part to difficulties with data collection in general, as well 
as the sensitive nature of the topic, it is unlikely that the MoH currently has 
national data about the average age at first sexual activity. Aside from a lack of 
necessary data, many parents may feel uncomfortable about vaccinating a child or 
adolescent for a sexually transmitted disease. In Honduras, where cultural norms 
about the permissibility of sexual activity outside of marriage are still restrictive 
of women's behavior, it is not hard to imagine parents' unwillingness to comply 
with such a vaccination. Despite possible cultural uncertainty about a vaccination 
for a sexually transmitted infection, my informants, especially at the grassroots, 
seem to believe that Hondurans would embrace a vaccine for cervical cancer. 
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Feasibility 
Pap Smears 
Clearly, implementing a Pap-based prevention program in Honduras is feasible 
since one has been in place since 1991. The MoH's recent "Strengthening 
Project" suggests that within the Ministry there is hope that improvements to this 
program can be made. Their assessment of the main weaknesses of the program 
includes poor linkages within the health care infrastructure and lack of 
compliance to guidelines, or quality control. These major barriers affect the 
overall effectiveness of the program and will be important to consider for any 
prevention effort. 
VIA 
The existence of a Pap-based prevention program, which is in many ways more 
resource intensive than a VIA-based effort, suggests that much of the 
infrastructure necessary for a VIA-based program is already in place. The major 
structural changes required for implementing a VIA-based program is a shifting 
down of screening service provision from physicians to nurses and LHAs; as well 
as overcoming physician (mainly gynecologists) resistance to these changes. 
Lower level providers would need training in VIA and cryotherapy, for which 
modules already exist that have been implemented successfully in similarly 
resource-poor settings. Refresher courses, much like the regional trainings 
Honduran LHAs already attend, could serve as a way to maintain high quality 
services. Although such a major training endeavor would require a significant 
time and financial commitment up front, the money saved from laboratory fees 
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could be put towards this end. Some initial investment for cryotherapy equipment, 
assuming a see-and-treat approach is implemented, would also be necessary. 
Despite the initial investments required, my health sector informants report that a 
single-visit approach with VIA and cryotherapy is feasible but will require a lot of 
convincing of physicians. My P AHO informant reported a two year process of 
advocating for a see-and-treat program in El Salvador with MoHand National 
Cancer Institute officials before being able to implement a pilot program. Once 
providers were convinced of VIA's efficacy, the program was quite successful. 
She reports great frustration at the hesitance on the part of providers and MoH 
officials to consider VIA since Pap-based approaches, as they are currently 
structured, are not effective. 
Similar concerns were raised by the gynecologists consulted by my MoH 
informant. Although a see-and-treat approach is feasible from a physical and 
human resources perspective, these Honduran gynecologists simply do not see a 
VIA-based program as feasible. Their main concern, as detailed above, is VIA's 
high false positive rate which, they claim, makes it inappropriate for 
institutionalizing at a national level. Perhaps this resistance could be limited by 
using the success of programs in neighboring El Salvador. After almost a year in 
operation, the program has been very well accepted and no women have suffered 
serious complications from the immediate delivery of treatment. Perhaps a similar 
marketing strategy in Honduras could soften the resistance of gynecologists who 
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are currently open to the idea of a small, VIA-based pilot program but find the 
idea of a national program unacceptable. 
HPV Vaccine 
The successes of Honduras' childhood vaccination campaigns suggest that an 
HPV vaccine program is probably feasible. The ovetwhelming success of the 
current childhood immunization program is due in part to a major decentralization 
of services so that vaccines are available at all health centers at all times; an 
immtmization registry to allow for recordkeeping and tracing of unvaccinated 
children; and a well-maintained cold chain to allow for effective vaccine 
maintenance (Secretaria de Salud 2002). Although the target age group would 
likely be young adolescents, not infants, these same infrastructure and systems 
management mechanisms would facilitate smooth implementation of a vaccine-
based prevention program. Because any vaccine program will also require 
secondary screening efforts, at least during the initial period, either Pap or VIA-
based screening would need to continue. 
Although current childhood immunization programs could help pave the way for 
smooth implementation of a vaccine-based prevention effort, there are still 
significant hurdles. Aside from the fundamental issue of the vaccine still being in 
the early stages of development, there are more concrete barriers to overcome. 
Ideally, adolescents would need to be vaccinated prior to onset of sexual activity 
to ensure no previous exposure to HPV. It is not clear whether the MoH has 
accurate data about the average age of onset of sexual activity in Honduras. Once 
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this age is established, what is the best way to capture this age cohort? Children 
this age tend not to utilize health care services as frequently as do infants. Thus, a 
standard clinic-based approach to immunization would likely be ineffective. 
While school could prove an ideal locale, many poor mral children, especially 
girls, are no longer attending school by adolescence. This suggests the need for 
some sort of mobile outreach effort, which would certainly complicate the 
maintenance of the cold chain. Although these barriers are all surmountable, 
policy planners would need to be very creative in developing a program that could 
overcome these obstacles to implementation. 
Table I: Summary Evaluation Table 
Criteria Pap Smears VIA 
Efficacy Sens: 44%-78% Sens: 66%-96% 
Spec: 91%-96% Spec: 64%-98% 
Effectiveness 8-73% in the UK 26% J, in incidence* 
0% in Honduras 34.9% ,J. in invasive 
12% tin incidence* CA** 
13.5% tin invasive 
CA** + 
Cost-effectiveness Incremental Cost- Incremental Cost-
effectiveness ratio effectiveness ratio of 
(US$/1ife years) 6 $263/life years** 
times that of VIA** 
++ 
Equity 0 ++ 
Acceptability 0 0/+ 
Feasibility 0 01+ 
0: denotes a neutral evaluation with Paps serving as the baseline measure 
+· better than Paps 
worse than Paps 
HPVVaccine 
100% for preventing 
persistent HPV16/18 
infection 
47% ,J. in invasive 
CA*** 
++ 
Estimated cost of 
$200 for 3 doses and 
all direct medical 
costs involved 
--
+ 
0/+ 
01+ 
*Goldie, Kuhn and Denny (2001) model based on once in a lifetime screening at age 35 
**Mandelblatt, Lawrence and Gaffikin (2002) model based on screening every 5 years in women 
aged 35 to 55 
***Hughes, Gamet! and Koutsky (2002) model based on HPV161!8 vaccine with 95% coverage, 
75% efficacy and 10-year immunity 
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Recommendations 
From a purely medical perspective, a cervical cancer prevention program should 
apply the most accurate screening method available to bring about the best 
possible results. Within a policy context, especially in a low-resource setting such 
as Honduras, the accuracy ofthe screening method is but one of several important 
criteria that need to be considered to make recommendations about an effective 
program. Such a program should yield decreased incidence of and mortality from 
cervical cancer by employing a screening method that is cost-effective, simple, 
easy to apply, with minimal side effects or complications, and is equitable and 
culturally acceptable. This is a high demand that, under the constraints of the 
current health infrastructure in Honduras, perhaps cannot be met completely. 
However I would suggest that a see-and-treat approach of VIA with immediate 
cryotherapy when necessary would come closer to meeting these goals than do 
current Pap-based programs. 
Although Pap-based screening programs have, perhaps by default, become the 
gold standard for effective screening programs in the developed world, they 
simply have not delivered the same benefits in Honduras. After over twenty years 
of a Pap-based prevention program, incidence and mortality rates are still 
unacceptably high. I would contend that this does not reflect inherent weaknesses 
in Pap smears as a screening method but instead exacerbates the broader, service 
delivery issues that are complicated by a Pap-based program. Most of these issues 
are simplified by a see-and-treat approach and address the specific concerns 
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raised by the MoH in their own recent assessment of Honduras' current 
prevention efforts. As elucidated earlier, their major concerns were a low demand 
for services, poor networking within the healthcare system, and a lack of 
compliance to norms. 
Low demand for services 
Based on the relatively high adherence rates (~60% nationally but closer to 85% 
in major urban areas), I would suggest that the greater concern is not demand for 
services but access to them (Secretaria de Salud 2002). A see-and-treat approach, 
which can offer a much broader coverage area since nurses and LHAs would 
provide prevention services, could significantly alter utilization rates, most 
specifically in currently underserved rural areas. This could drive up demand for 
services, as well as significantly improve the equity of the program. This 
decentralization of preventive services could have additional benefits outside of 
the arena of cervical cancer as LHAs and nurses expand their scope of practice 
and underserved patients gain increased access to care. 
Poor networking within the healthcare system 
One of the major complaints about the current-Pap based system is that many 
women never get their results, and that even those who do often do not receive 
adequate referrals or carmot return for follow-up care. A see-and-treat approach 
mitigates many of these concerns. The provision of immediate results not only 
ensures that women will get their results, but also offers an opportunity to provide 
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counseling to ensure that they understand them. Moreover, the ability to offer 
immediate treatment in the form of cryotherapy minimizes loss to follow-up. 
Although women with invasive cancer will still need referral and linkage to the 
broader health care network, the ability to provide immediate results and 
treatment will significantly decrease the number of women who need follow-up in 
a more specialized setting. 
This ability to combine screening with immediate treatment adds significantly to 
the effectiveness and the cost-effectiveness of the program. In Mandelblatt, 
Lawrence and Gaffikin's (2002) model, VIA with referral to another facility for 
treatment was compared to VIA with immediate cryotherapy as necessary. If 
women 35 to 55 years old are screened every five years, the see-and-treat 
approaches results in a 30.8% reduction in incidence and 34.9% reduction in 
mortality whereas the screen and refer approach results in an 8.3% reduction in 
incidence and 12.3% reduction in mortality. 
Lack of compliance with norms 
Implementing a new prevention program, which would require training of new 
service providers, would offer an ideal opportunity to establish appropriate 
clinical care guidelines and recommendations as well as mechanisms for ensuring 
they are met. Most pilot see-and-treat programs have built refresher courses into 
the training and quality control standards for screening and treatment providers. 
Such courses could help to ensure the degree of compliance to norms that is 
lacking in the current Pap-based program. These quality assurances would also be 
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fundamental in helping gynecologists, who are currently resistant to a see-and-
treat approach, feel more confident in its outcomes. Their advice in establishing 
appropriate cryotherapy treatment protocols could be helpful in ensuring a 
clinically sound program as well as securing physician buy-in to the new policy. 
Because quality control is of stated concern to the MoH as well, attention to 
quality issues would need to play an integral role in development of any new 
prevention program. 
A see-and treat approach would not only address many of the concerns raised by 
the MoH regarding the current Pap-based program, but would also fit well into the 
broader health policy agenda currently facing Honduras. The confluence of 
several events makes this an ideal time for Honduras to consider moving towards 
a see-and-treat approach to reduce the impact of cervical cancer. Internally, the 
MoH has recently enjoyed the much-publicized success of its program to reduce 
maternal mortality. The overwhelming success of this program not only illustrates 
the ability of the public health infrastructure to perform well, but also indicates a 
shift in priority towards women's health issues. Cervical cancer prevention 
advocates would do well to make use of this window of opportunity while it still 
exists. 
External factors are also forcing the policy window open. Among them is 
increased attention to the growing HIV/AIDS problem in Honduras, which could 
have a profound impact on cervical cancer if it is not well controlled. US AID 
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announced renewed efforts and funding to stem this growing epidemic in 
Honduras. Such attention will serve to increase public awareness of sexually 
transmitted infections and prevention efforts. This can help pave the way for 
easing cultural restrictions around discussing and accessing prevention services 
for other reproductive health issues such as cervical cancer. 
The ACCP and other international agencies interested in cervical cancer 
prevention have been actively pushing the issue of re-assessing prevention efforts 
in the developing world. Over the past year, numerous articles addressing this 
topic have flooded the gynecologic, cancer and international health journals, 
sparking debate among researchers, clinicians and program planners. This 
academic discussion coincides with the continued implementation of numerous 
pilot programs and clinical trials throughout the developing world. Even 
traditionally conservative professional organizations such as the American 
College of Obstetricians and Gynecologists (ACOG) have entered the debate, 
issuing statements on the need for a re-consideration of prevention efforts in the 
developing world. They have gone so far as to deem see-and-treat approaches as 
appropriate within this context. This is significant: American gynecologists, who 
are accustomed to the benefits of Pap-based prevention, are indirectly endorsing 
the idea that perhaps such policies are not as efficacious in the developing world. 
All of these activities suggest significant external activity that could be 
instrumental in helping to tilt the policy agenda in Honduras toward a new 
approach to cervical cancer prevention. 
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Such external influences are not new to Honduras. Especially since Hurricane 
Mitch, external assistance, both financial and technical, has been a major part of 
many development and health promotion policies. Even the "Strengthening 
Project" for the current Pap-based program received 65% of its funding from 
external sources, mainly an international development organization. Thus, the 
possibility for external assistance with a prevention program is certainly not new. 
Within this context, I recommend that the MoH implement a pilot see-and-treat 
prevention program. The program could be modeled after see-and-treat 
approaches currently ongoing in other parts of Central America. These programs 
are centered on the concept of bringing prevention and some treatment services 
into the primary care setting. This shift requires slowly building gynecologist 
acceptance, and training lower-level providers such as nurses and LHAs in the 
practice of VIA and, for more skilled nurses and LHAs, cryotherapy. The 
program will allow for much broader coverage of prevention services, especially 
in poorly served rural areas. Starting small, with a pilot program, offers the 
benefit of maximizing benefits while minimizing risks. It also allows more time 
for advocacy before initiating broader implementation plans. This advocacy will 
be fundamental to getting support from gynecologists, whose input is crucial for 
the program to work. Benefits of such an approach include the following: 
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Improved equity: All of my key informants expressed concerns about low 
coverage rates, especially in rural areas. A VIA-based approach will greatly 
improve coverage, especially for poor, rural women. 
Rapid return of results: Much like coverage, the issue of delay in getting results 
was mentioned by all informants as a factor in the poor effectiveness ofthe 
current program. VIA solves this problem completely without major effort. 
Primary care focus: A see-and-treat approach mirrors efforts in much ofthe 
developing world to shift care out ofhospitals and to more community-based, 
primary care settings. Such a shift not only uses resources more effectively but 
also makes them more accessible to a broader segment ofthe population. This 
change also requires a move to less invasive treatments, when appropriate. Within 
the context of cervical cancer, this is ideal. A Honduran woman diagnosed with 
cervical cancer either gets a conization or, assuming she is past childbearing 
years, a hysterectomy (MoH informant 2005). However, if her cancer could be 
detected much earlier through screening, she could avoid these more invasive 
procedures and instead just get treated with cryotherapy. The lower costs in time, 
resources, and morbidities for both the patient and the health care system could be 
substantial. 
Increased role of LHAs: LHAs are a greatly underused resource. Their 
integration within the community generally makes them trusted advisors. Thus, 
74 
their ability to provide much needed education about cervical cancer prevention is 
invaluable. Moreover, their training in VIA could open the door to more expanded 
roles. Some LHAs in southern Honduras currently manage birth control supplies 
for their communities, dispensing pills and giving Depo Provera shots. VIA 
training could be the next step in greater care provision in rural areas. Should a 
vaccine program be implemented in the next 10 to 15 years, LHAs would be ideal 
providers. 
A see-and-treat approach, implemented first on a small scale, could be integral to 
mitigating the barriers that prevent the Pap-based program from being more 
effective. Models from neighboring Central American countries suggest that this 
will be the case. Financial support and technical assistance form international 
health and development organizations could help to ensure minimal costs to the 
MoH. If effective and implemented more broadly, such a policy could begin to 
decrease the significant morbidity and mortality of cervical cancer in Honduras. 
Despite the possible benefits of such a policy, numerous unknowns remain. 
Although modeling suggests that VIA is both more effective and more cost-
effective than Pap- and vaccine-based programs, we are still several years from 
evidence that could demonstrate positive effects on disease incidence and 
mortality. During that period, significant advancements in the development of 
HPV vaccines and HPV DNA testing could make these more viable alternatives 
for the future. Both of these alternatives currently lack the necessary effectiveness 
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data to support their widespread use. However, such data should be forthcoming. 
If these methods prove to be successful, we can hope that they will also soon 
become more cost-effective so that they can be implemented even in resource-
poor settings. Any of these alternatives share in the advantage of making use of 
LHAs to provide service in a more equitable manner. Only in these ways can we 
ensure a program that results in decreased incidence and mortality of this 
preventable disease for all women. 
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Appendix A: Survey of Experts on Cervical Cancer in Honduras 
"Hello, this is Jessica Morse. I am a graduate student from the University of North 
Carolina at Chapel Hill. I emailed you earlier about participating in a telephone interview 
for my research study entitled "A Policy Analysis of Cervical Cancer Prevention in 
Honduras". Your participation in this survey is completely voluntary. This means that 
you do not have to participate in this survey unless you want to. 
Did you have a chance to read the information I emailed you about participating in 
research studies?" 
If "yes": "Do you have any questions or concerns about the research I am doing?" 
- Answer all questions. 
- If no questions or when all questions completely answered: 
"Please be assured that I will not identify you by name, but only by general 
position, such as "Health Care Provider," "Researcher," "Organization 
Representative," or "Ministry of Health Official." If you have any questions about 
this study, please contact me (Jessica Morse, Jessica morse@med.unc.edu) or 
the University of North Carolina at Chapel Hill Office of Human Research Ethics 
(IRB subjects@unc.edu). As we discussed, I would like to tape this interview to 
assure that I have as accurate a picture as possible of your respon~es. I will be 
happy to send you a transcript if you like." 
"Do I have your permission to begin asking questions?" 
"Do I have your permission to tape this interview?" 
If "no": Read Telephone Script to obtain informed consent. 
After obtaining informed consent, begin here: 
Thank you for helping me to study cervical cancer prevention programs in Honduras. 
Because I know your time is valuable, I will get right to the point. I want to get your 
views on some general questions and also some questions about specific areas of the 
Honduran health care system. You have special insight into each of these questions, 
and I value your responses. 
1. The Honduran health system has used Papanicolau (Pap) screening programs 
for cervical cancer prevention for years. What improvements might be made to this 
prevention program that would help to further reduce cervical cancer morbidity and 
mortality? 
2. What do you think is the single most important reason for Honduras' cervical 
cancer morbidity and mortality rates? 
3. And what about other reasons? 
4. You have had experience with cervical cancer programs, either by implementing 
them or by conducting research on cervical cancer, or both. I want to know what factors 
you think help or hinder these programs. Please tell me anything that comes to mind. 
Follow Up to 'What do you mean?": Well, any factors, like culture or politics or 
economics or anything else. 
5. I know how challenging it is sometimes to be able to tell whether programs are 
succeeding. If you were trying to implement a new cervical cancer screening program, 
what measures of success would you use? 
Follow Up to "What do you mean?": For example, how would you measure whether it is 
effective, whether it is acceptable to women, whether it is politically feasible, and 
whether it is financially feasible? 
6. Now I'd like to talk for a minute about a different screening technique called VIA, 
or visual inspection with acetic acid. Some research suggests that it can be better than 
Pap smears in some settings because it costs much less, and because the patient can 
get her results immediately. Do you think this could be an effective method in 
Honduras? Please tell me why you think this. 
Follow-up if necessary: Could such a test be feasibly incorporated into a widespread 
program? Please tell me why or why not. 
Follow-up if necessary: Do you think Honduran women would accept visual inspection 
with acetic acid (VIA)? Please tell me why you think this. 
7. What about the HPV vaccine to prevent cervical cancer that is now being tested 
in other parts of Latin America? Do you think it could be used in Honduras? Please tell 
me why you think this. 
Follow-up if necessary: Do you think an HPV vaccine could be feasibly implemented in 
a widespread program? Please tell me why you think this. 
Follow-up if necessary: Do you think Honduran women would accept an HPV vaccine 
for prevention of cervical cancer? Please tell me why you think this. 
Now I have a few last questions. 
8. Where would you say improving cervical cancer morbidity and mortality falls on 
the agendas of the current administration and the Ministry of Health, understanding the 
many other needs that Hondurans have? 
Why do you think cervical cancer falls where it does on the health care agenda? 
9. Who are the key players need to support a cervical cancer prevention program? 
Why? 
Who might be the strongest opponents of a new program? Why? 
10. How long do you think it would take to see a new program accepted? 
How long do you think it would take to see the new program achieve results? 
11. Now I have just one last question: from your own perspective, and from the 
vantage point of the position you occupy, what do you see as the three main barriers to 
improving cervical cancer prevention in Honduras? 
We are done! Thank you again for answering these questions! Please do not hesitate 
to contact me if you have any questions about this interview or about my research study. 
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Appendix B: Key Informant Interview Citations 
1. Government Sector 
Regional Level 
Zona 4 Director; Ministry of Health 
Conducted by telephone 6/13/05 
2. Clinical Care Provision Sector 
National Level 
Chief of Division of Research, Evaluation & Statistics; ASHONPLAFA 
Conducted via email (written responses to survey) on 5/10/05 
3. Non-Governmental Organization/Community-Based Organization Sector 
Local Level 
Director; Communidades Unidadas 
Conducted via email (written responses) with in-person follow-up on 6/17/05 
4. International Health Organization Sector 
International Level 
Project Manager for Non-Communicable Diseases; P AHO 
Conducted via telephone on 5/31105 
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